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Trauma to the spinal cord causes permanent disability to more than 180,000 people every
year worldwide.The initial mechanical damage triggers a complex set of secondary events
involving the neural, vascular, and immune systems that largely determine the functional
outcome of the spinal cord injury (SCI). Cellular and biochemical mechanisms responsible
for this secondary injury largely depend on activation and inactivation of specific gene
programs. Recent studies indicate that microRNAs function as gene expression switches
in key processes of the SCI. Microarray data from rodent contusion models reveal that
SCI induces changes in the global microRNA expression patterns. Variations in microRNA
abundance largely result from alterations in the expression of the cells at the damaged
spinal cord. However, microRNA expression levels after SCI are also influenced by the
infiltration of immune cells to the injury site and the death and migration of specific neural
cells after injury. Evidences on the role of microRNAs in the SCI pathophysiology have
come from different sources. Bioinformatic analysis of microarray data has been used to
identify specific variations in microRNA expression underlying transcriptional changes in
target genes, which are involved in key processes in the SCI. Direct evidences on the role
of microRNAs in SCI are scarcer, although recent studies have identified several microRNAs
(miR-21, miR-486, miR-20) involved in key mechanisms of the SCI such as cell death or
astrogliosis, among others. From a clinical perspective, different evidences make clear
that microRNAs can be potent therapeutic tools to manipulate cell state and molecular
processes in order to enhance functional recovery. The present article reviews the actual
knowledge on how injury affects microRNA expression and the meaning of these changes
in the SCI pathophysiology, to finally explore the clinical potential of microRNAs in the SCI.
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INTRODUCTION
Spinal cord injury (SCI) is a dyscapacitating pathology with a
global-incident rate estimated at 23 new traumatic SCI cases per
million in 2007 (180,000 new cases/year; Lee et al., 2013). Recov-
ery, even partial, from SCI was considered unachievable until the
early 1980s when David and Aguayo (1981) demonstrated that
spinal axons could regenerate under appropriate conditions. This
seminal work initiated a burst of research aimed to understand the
pathophysiology of the SCI and the development of therapeutic
tools. The capacity of microRNAs to regulate cell state and func-
tion through post-transcriptionally silencing hundreds of genes
are being acknowledged as an important actor in the pathophys-
iology of SCI. In this article, we review the known and potential
roles of microRNAs in SCI and their possible therapeutic applica-
tion. The article begins with an overview of the pathophysiology of
SCI and the gene programs involved, followed by a general picture
of microRNA biogenesis, function, and regulation, particularly
in the central nervous system (CNS). Afterward, we discuss the
observed global changes in microRNA expression following SCI
and the role of mechanisms regulating microRNA biogenesis on
SCI. We next explore the contribution of microRNA in the reg-
ulation of key processes of SCI such as inflammation, cell death,
regeneration, or gliosis. The review ends with a brief perspective
on the feasibility of microRNA-based therapeutics in the treatment
of SCI.
AN OVERVIEW OF THE PATHOPHYSIOLOGY OF THE SPINAL
CORD INJURY
The term spinal cord injury refers to the damage to the spinal
cord caused by trauma or disease but also to the physiological
response that develops after injury and that largely determines
the functional deficits that will face the injured person. Although
most SCI are traumatic, inflicted by mechanical causes due to acci-
dents or violence, there are also a number of non-traumatic SCIs,
mainly due to discopathies and tumors (Biering-Sorensen et al.,
1990). The pathophysiology of the SCI is a complex intermin-
gled set of events, responses, mechanisms, and processes, affecting
the nervous, vascular, and immune systems, that develop dur-
ing the months following the initial damage. Most participating
cells reside in the spinal cord, but others are summoned to the
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 53 | 1
Nieto-Diaz et al. MicroRNAs in spinal cord injury
injury site from the circulatory system. A brief description of the
pathophysiology is provided in the following paragraphs. Detailed
descriptions can be obtained in different reviews (Mautes et al.,
2000; Dumont et al., 2001; Profyris et al., 2004; Liverman et al.,
2005; Rowland et al., 2008; Oyinbo, 2011).
In the traumatic SCI, the mechanical trauma causes the com-
pression, stretching, laceration, or transection of the spinal cord.
The most common form of SCI is a compressive–contusive-type
injury in which displaced components of the vertebral column,
exert force on the cord causing both immediate traumatic injury
and often sustained compression (Rowland et al., 2008). Once
compression and contusion surpass structural thresholds, phys-
ical and biochemical alterations of the cells induce a cascade of
systemic and local events that constitute the primary damage
(Oyinbo, 2011). Local events include axon severing, membrane
rupture and death of neurons, glia and endothelial cells. Surviv-
ing neurons at the injury site respond firing action potentials that
shift the local levels of ions together with the ions released due
to membrane shear. The resulting ion concentration reaches toxic
levels that kill the nearby neurons. The barrage of action poten-
tials also causes the release and accumulation of neurotransmitters
that will cause further neuron and glial cell death by excitotoxicity.
Mechanical trauma causes intraparenchymal hemorrhage (mainly
in the small vessels of the gray substance) and, consequently, the
disruption of the blood–spinal cord barrier together with edema
and swelling at the spinal cord (Mautes et al., 2000). Vasospasm
and thrombosis in the superficial vessels accompany hemorrhage
causing hypoxia, ischemia, and increasing neural cell death. At a
systemic level, primary damage causes a transient increase in sys-
temic blood pressure that is followed by a prolonged hypotension
(either hemorrhagic or neurogenic) causing further oxygen depri-
val to the spinal cord. Hypoxia – together with ion shifts inside and
outside the neuron – seems to cause a temporal switch off of the
spinal cord function at and below the injury site known as spinal
shock.
In the minutes to months that follow the initial damage, the
secondary phase of the SCI takes place. This secondary phase
comprises several interrelated damage processes including vascu-
lar alterations, biochemical disturbances and cellular responses
that lead to an inflammatory response and cell death that signif-
icantly expand the area of damage. Vascular alterations resulting
from hemorrhage and ischemia are central constituents of the sec-
ondary injury cascade. Reduced perfusion of the spinal cord due to
vasospasm and hypotension is followed by a period of reperfusion,
which increases the production of oxygen- and nitrogen-derived
free radicals [superoxide, hydroxyl radicals, nitric oxide (NO), per-
oxynitrite] already being produced during the period of ischemia
(Dumont et al., 2001). All these species contribute to oxidative
stress and exacerbates damage and cell death. Alterations in the
vascular system also include the disruption of the blood–spinal
cord barrier that extends far beyond the injury site for days and
even weeks after injury. Release of cytokines [interleukin (IL)-1β,
tumor necrosis factor-α (TNF-α)], matrix metalloproteinases,
reactive oxygen species (ROS), etc., contribute to enhance vas-
cular permeability (Mautes et al., 2000; Donnelly and Popovich,
2008) and – together with upregulation of cell adhesion molecules
(CAMs and selectins) by endothelial cells (Mautes et al., 2000;
Profyris et al., 2004; Donnelly and Popovich, 2008) – participate
in the recruitment and infiltration of immune cells to the injured
spinal cord.
Immune cells develop a key role in the pathophysiology of
SCI. Neutrophils arrive to the injury site in the first hours after
injury [peaking at 1 day post-injury (dpi) in rats and 1–3 dpi
in humans, see Fleming et al., 2006] and disappear during the
first week, although some evidences indicate a continued pres-
ence for long times (180 dpi in rats, according to Beck et al.,
2010). Neutrophils remove debris, but mainly release assort-
ments of proteins, including proteolytic and oxidative enzymes
that “sterilize” the area but also contribute to extend tissue dam-
age (Taoka et al., 1997). Neutrophils also release signaling proteins
that attract macrophages. Macrophages resulting from the activa-
tion of spinal cord microglia or from blood monocytes infiltrate
the injury in the first days after the injury, presenting a peak dur-
ing the first week and persisting for months (Fleming et al., 2006).
Microglial activation is triggered early after injury and induces
a morphological and functional change in the phenotype of this
cell, from a resting, ramified phenotype to a phagocytosis-capable,
“macrophage-like” phenotype (Byrnes et al., 2006). Macrophages
remove debris and dead cells, present antigens, and release pro-
inflammatory and protective cytokines, ROS, NO, and proteases
(Fleming et al., 2006). T lymphocytes enter the injured spinal cord
mainly 1 week after injury. T cells are responsible for cell-mediated
adaptive immunity, although their role in SCI remains controver-
sial (Fleming et al., 2006). In rat models, it seems that immune
cells tend to maintain or reduce their presence after this first burst
of immune response following SCI. However, a recent study in
rats demonstrates that immune cells present a time-dependent
multiphasic response, with a late phase that mainly involves a
peak of macrophages at 60 dpi (Beck et al., 2010). Contrary to the
mixed beneficial and detrimental effects on the immune response
in the initial phase, this late phase seems to be mainly benefi-
cial and its blocking causes further functional deficits (Beck et al.,
2010).
All previous events have strong effects on neural cells. Necrotic
cell death initiated by the mechanical trauma spreads during the
secondary phase due to excitotoxicity and the accumulation of free
radicals (ROS and RNS) released by immune cells or during reper-
fusion. Free radicals cause lipid peroxidation as well as oxidative
and nitrative damage to lipids, proteins, and nucleic acids, induc-
ing the lysis of the cell membrane, altering the cytoskeleton and
the organelles, and ultimately causing the death of neural cells
(Oyinbo, 2011). Apoptosis and other forms of programed cell
death are also important actors in secondary damage after SCI.
Programed cell death seems to occur in at least two phases: an
initial phase, in which apoptosis accompanies necrosis and a later
phase, which is predominantly confined to white matter and that
affects oligodendrocytes and microglia (Profyris et al., 2004). Cal-
cium influx and possibly signaling through Fas/CD95 pathway are
among the triggers proposed for programed cell death although
other mechanisms may be also acting, including lost of trophic
support (Liverman et al., 2005; Rowland et al., 2008).
Apoptosis of oligodendrocytes results in extended demyelina-
tion, the loss of the oligodendrocyte myelin sheath that insulate
nerve axons and permit effective nervous signal conduction. As a
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consequence, axons crossing the injured segment/s but deprived
from myelin sheath and experiencing alterations in the ion chan-
nels become unable to transmit signals to the brain and the
body, even though they remain intact. Axotomy (axon section-
ing) is also a major factor in SCI. Depending on aspects such as
distance of axotomy to cell body, trophic support or neuronal
type, the fate of axotomized neurons will differ strongly. A sig-
nificant proportion of neurons, being severed close to the cell
body or lacking enough tropic support, die after axotomy. Oth-
ers retract the severed axon and develop a terminal retraction
bulb. Conversely, some surviving neurons develop a regenerat-
ing response. These neurons experience hypertrophy of the cell
body due to the increased synthesis of proteins that will be used
in an attempt to regenerate the severed axon. Within this pro-
regenerative response, intact neurons can also develop sprouts
(collateral axonal branches) that may rewire unconnected targets
(sometimes with undesired side effects). However, axon growth
is strongly if not completely inhibited due to several inhibitors
present at the injured spinal cord. Much of this inhibition is
due to molecules associated to the oligodendrocyte myelin, such
as NOGO, and other are consequence of the changes experi-
enced by the astrocytes following injury. Astrocyte reactivity after
SCI involves cellular changes characterized by an initial hyper-
trophic and a late hyperplasic response (Fawcett and Asher, 1999;
Sahni et al., 2010). During the hypertrophic response, reactive
astrocytes present a characteristic enlarged somata with thick-
ened processes and upregulation of intermediate filament proteins,
such as glial fibrillary acidic protein (GFAP) and vimentin (Pekny
and Pekna, 2004). This initial hypertrophic response protects
neural cells by up-taking the potentially excitotoxic glutamate,
producing oxidative stress scavengers and repairing the blood–
spinal cord barrier (Faulkner et al., 2004; Sofroniew, 2005). In
the following hyperplastic phase during the subacute and chronic
phases of the SCI, newly proliferated astrocytes with thinner pro-
cesses forms a dense scar in the damaged area that inhibits of
axon regeneration (Fawcett and Asher, 1999; Silver and Miller,
2004).
In the months and years that follow the damage, the SCI
becomes chronic. Cell death, scarring, gliosis, and other local
alterations of the tissue lead to the formation of cavities filled
of fluid and surrounded by glial scar that can extend for sev-
eral segments above and below the injury site (Liverman et al.,
2005). Myelin loss and alterations in the functioning of the
ion channels can lead to changes in the surviving neurons and
dependent networks leading to chronic neuropathic pain and/or
spasticity.
GENE EXPRESSION CHANGES AFTER SPINAL CORD INJURY
Most cell functions, responses, and phenotypic changes depend on
the activation and/or suppression of a large number of transcrip-
tional pathways (Di Giovanni et al., 2003). Microarray analyses
in SCI models have identified gene expression changes that, to
some extent, can be observed across different studies and even
across different strains or species (Di Giovanni et al., 2003; Velardo
et al., 2004). Prominent expression changes in the spinal cord
following injury comprise clustered expression changes in genes
associated to:
TRANSCRIPTION AND STRESS RESPONSE
Clusters including factors such as NF-κB (nuclear factor kappa-
light-chain-enhancer of activated B cells), c-fos, HSP-70 (70 kD
heat shock protein) become upregulated early after injury and
continue for at least 24 h (Song et al., 2001). Activation of tran-
scription factors such as NF-κB or interferon regulatory factor
(IRF)-1 mediates the increased expression of pro-inflammatory
genes and modulates pivotal processes such as apoptosis or regen-
eration (Song et al., 2001). On the other hand, there is an early
increase in chaperone expression (HSP-70) together with metal-
lothioneins 1 and 2 (Aimone et al., 2004) that may protect cells
from protein damage or oxidative stress. Further anti-oxidative
stress genes become upregulated at much later times, including
superoxide dismutases (SODs) 1 and 2, catalase, and glutathione
peroxidase (GPX; Aimone et al., 2004).
INFLAMMATORY RESPONSE
Upregulation of pro-inflammatory genes, including cyclooxyge-
nase (COX)-2, interleukins IL-1β and IL-6, TNF-α, is observed
early after injury and persists during the first weeks to go back
to normal levels at 14 days (Carmel et al., 2001; Song et al., 2001;
Di Giovanni et al., 2003; Zhang et al., 2004). Chemokines involved
in immune cell attraction [monocyte chemotactic protein (MCP)-
1, macrophage inflammatory protein (MIP)-1β] and adhesion
molecules participating in cell infiltration (integrins, intercellular
and vascular CAMs, cadherins, and selectins) are also upregu-
lated during the first hours after injury (Aimone et al., 2004).
Changes in the expression of inflammatory genes take place in
different spinal cord cells but has been particularly studied in
microglia. According to a profiling study developed by Byrnes
et al. (2006), activated microglia first express (peak at 4–24 h) pro-
inflammatory molecules, including IL-1β, IL-6, CCL2 [chemokine
(C–C motif) ligand 2]/MCP-1, CXCL2 [chemokine (C–X–C
motif) ligand 2]/M1P2α, involved in the recruitment of immune
cells to the damaged area. A second pulse of change in microglial
gene expression occurs later (3–7 dpi in rats) and involves genes
coding for cytochrome b-245 light chain protein (CYBa), cathep-
sin Y, Galectin-3, microglial response factor (MRF)-1, P38, cyclin
D1, caspase 1, and leukocyte surface antigen CD53/OX44, that
participate in the regulation of the immune response, phagocy-
tosis, production of ROS, proliferation, and cell death. Other
immune response genes related to phagocytosis including the clas-
sical complement pathway and the FC receptors show a persistent
upregulation after injury (Aimone et al., 2004).
NEURON-ASSOCIATED GENES
A large cluster of genes coding for proteins involved in the potas-
sium, calcium, and sodium pumps and channels as well as in
synapsis, cell excitability, and neurotransmission show a signifi-
cant decrease during the first week (Carmel et al., 2001; Velardo
et al., 2004; De Biase et al., 2005; Wu et al., 2005). This decrease
can reflect changes in the gene profile of the neurons but it
may also reflect the advance of neuronal cell death that takes
place after injury (Carmel et al., 2001; De Biase et al., 2005).
Attempts of axonal regeneration in the weeks following injury
are also accompanied by expression changes in a large group of
genes that includes the overexpression of several plasticity and
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regeneration-associated proteins (Ninjurin, Coronin 1b, Rab13,
Growth Associated Protein-43, Neuritin, Ankyrin, Myelin oligoden-
drocyte glycoprotein, and cAMP-related genes; Carmel et al., 2001;
Song et al., 2001; Di Giovanni et al., 2003, 2005b).
CELL CYCLE AND CELL DEATH
Changes in the expression of cell cycle genes has been detected
24 h after injury, including upregulation of c-myc, pcdna, gadd45a,
and cyclins (Di Giovanni et al., 2003). Activation of cell cycle genes
may induce apoptosis in post-mitotic cells and, thus underlie post-
SCI apoptosis of neurons. They may also be involved in astrocytic
proliferation during the glial scar formation (Di Giovanni et al.,
2003). Pro-apoptotic and anti-apoptotic genes also show signifi-
cant expression changes, including upregulation of caspase-3, Bax,
Bak-1 in the first week after SCI and the later upregulation of
protective PI3K and Stat3 and downregulation of pro-apoptotic
GSK-3 (Carmel et al., 2001; Aimone et al., 2004). In addition, it
has been observed the upregulation at 24 h of genes coding for
different growth factors [transforming growth factor-β (TGF-β),
platelet-derived growth factor, vascular endothelial growth factor]
and anti-apoptotic proteins (survival of motor neurons proteins),
which may contribute to prevent neural cell death (Song et al.,
2001).
VASCULAR SYSTEM REGULATION AND ANGIOGENESIS
Hemorrhage and other early vascular events are reflected in the
expression profile. Blood coagulation genes – platelet factor 4
(CXCL4), coagulation factors VIII, protein C, etc., – appear over-
expressed in the first 24 h after injury and some remain for several
weeks (Chamankhah et al., 2013). Genes such as angiopoietin are
increased in the injury area in the week that follows the dam-
age (Aimone et al., 2004). Other dysregulated genes related to
vascular events include HIG (hypoxia-induced gene), which is
downregulated late after injury (Aimone et al., 2004).
CHANGES IN GLIAL CELLS
Although less explored in global profile studies, there are impor-
tant changes in gene expression in the glial cells related to astrocyte
reactivity and the formation of the glial scar, as well as to the prolif-
eration and remyelination attempts of oligodendrocytes. Among
the best-characterized genes related to astrocyte reactivity and glial
scar formation are those coding for GFAP, vimentin, and nestin,
intermediate filaments highly overexpressed in reactive astrocytes.
These genes are markedly upregulated during the first week after
injury (Carmel et al., 2001; Wu et al., 2005). On the other hand,
oligodendrocyte profiles are characterized by a decrease in cell spe-
cific genes due to the advance of oligodendrocyte death during the
first weeks followed by an increase in proliferation and myelination
genes (Wu et al., 2005).
MicroRNA BIOGENESIS, FUNCTION, AND REGULATION
As we have shown in the previous sections, SCI causes pro-
found cellular changes that result from dysregulation of sig-
naling pathways and structural proteins. Alteration of gene
expression following SCI is likely accompanied by the post-
transcriptional regulation of these modified gene networks.
Among the known post-transcriptional regulators, microRNAs
have recently attracted much attention due to their ability to
inhibit mRNA translation.
MicroRNAs were first identified in C. elegans in 1993 (Lee et al.,
1993). A small non-coding RNA (lin-4) was shown to regulate
translation of lin-14 through RNA–RNA interaction. MicroRNAs
constitute an abundant class of highly conserved small non-coding
RNA molecules composed of 20–24 nucleotides in length, that
post-transcriptional regulate gene expression. More than 2500
mature forms of microRNA sequences have been identified in
humans (miRBase; Kozomara and Griffiths-Jones, 2011). MicroR-
NAs are transcribed from genomic DNA by RNA polymerase II or
III in the form of large primary transcripts (pri-miRNAs) with
functional secondary structures of stem-loop hairpins. The stem-
loops structures are recognized and cleaved by the complex formed
by the RNase III Drosha and the RNA-binding protein DGCR8,
which leads to liberation of a precursor microRNA (pre-miRNA).
Once processed, exportin 5 transports the pre-miRNAs from the
nucleus to the cytosol, where an enzymatic complex containing
Dicer process them to yield the 20- to 25-nucleotide duplex mature
miRNAs. One strand (passenger) of the duplex is degraded and
the other strand (guide) is integrated into a RNA-induced silencing
complex (RISC), which facilitates the binding of the microRNAs
to their target mRNA.
The predominant role of microRNAs in RISCs is to regu-
late post-transcriptional the expression of their target genes by
translational repression, mRNA cleavage, or mRNA decay. The
employed mechanism depends on the degree of complementarity
between the microRNAs and their target mRNAs. When microR-
NAs perfectly or near-perfectly pairs the targeted mRNAs, as
occurs in plants, cleavage of the mRNA takes place. On the con-
trary, when microRNAs imperfectly pair to their target mRNAs, as
usually occurs in animals, translational repression or decay (due to
microRNA-driven deadenylation) become the mechanisms medi-
ating gene regulation. In animals, microRNAs have been proposed
to downregulate gene expression mostly through the translational
repression (Krichevsky, 2007), although a recent study showed that
destabilization (and degradation) of target mRNAs is the major
mechanism of miRNA gene repression in mammals (Guo et al.,
2010).
Since microRNAs do not require perfect complementarity for
target recognition in animals, a single microRNA can regulate
multiple, even hundreds mRNAs (Lim et al., 2005; Baek et al.,
2008; Selbach et al., 2008). At the same time, each mRNA can
be regulated by many microRNAs (Krek et al., 2005; Krichevsky,
2007) and a given microRNA may have multiple binding sites in
the same mRNA, thereby enhancing its overall effect (Bhalala et al.,
2013). Computational predictions suggest that the more than 2000
known human microRNAs are able to repress the expression of
at least a 20–30% of all protein-coding genes (Krichevsky, 2007)
and up to the 60% according to Friedman et al. (2009) and Sayed
and Abdellatif (2011). Besides a single miRNA can tune protein
synthesis from thousands of genes, quantitative proteomics stud-
ies have found that the magnitude of the change is small under
physiological conditions (less than fourfold; Guo et al., 2010). In
fact, blocking microRNA biogenesis through DICER inhibition
has modest effects on cell differentiation and organism patterning,
although opposite results have also been reported (Kosik, 2010).
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MicroRNAs are common components of regulatory path-
ways, and in many cases constitute molecular on–off switches in
establishing cell fate and identity both under physiological and
pathological conditions. The power of this regulatory mecha-
nism lies in the unique ability of microRNAs to guide processes
and cellular functions through precise titration of gene dosage,
and the ability of a single microRNA to control the levels of a
large cohort of gene products. Because microRNAs target multi-
ple mRNAs, they can exert distributed control over broad target
fields of functionally related mRNAs as opposed to focusing their
control on a small number of genes in a “final common pathway.”
The action of an individual microRNA can lead to a cumulative
reduction in expression of multiple components of one specific
functional network, and several microRNAs may cooperatively tar-
get various mRNAs whose protein products are part of the same
molecular pathway (Krek et al., 2005; Krol et al., 2010; Sluijter,
2013). MicroRNAs are often physically clustered in the genome,
and these sets of microRNAs may target mRNAs with related
biological functions at short distances in their protein–protein
interaction map (Kim et al., 2009). Coordinated microRNA tar-
geting of closely connected genes seems to be prevalent across
pathways (Tsang et al., 2010). Thus, microRNAs provide broad
and robust transcriptional regulation that can be governed either
by individual microRNAs or by the combined action of multiple
microRNAs.
MicroRNA networks are often specialized for specific cell types
and there is a strong correlation between cell identity and pat-
terns of microRNA expression (Kosik, 2010). The anticorrelated
expression of microRNAs and their target mRNAs in develop-
mental transitions and the mutually exclusive expression of target
genes and microRNAs in neighboring tissues argues that microR-
NAs confer accuracy to developmental gene expression programs,
thus ensuring tissue identity and supporting cell-lineage decisions,
and reflect the basic role of miRNAs in establishing cell iden-
tity during development (Ebert and Sharp, 2012). MicroRNAs
also serve as a buffer to assist cells in coping with environmental
contingencies (Kosik, 2010). As markers of cell identity, miRNAs
encode a representation of multiple cell states that all correspond
to a single identity. That is, many different states comprise a
single identity because cells must retain their identities in the
face of both environmental changes and internal noise that can
result in large variations in molecular composition. MicroRNAs
are good candidates for setting boundary conditions upon coding
transcripts to restrict protein levels within a range of values that
maintain cell identity in the face of homeostatic compensatory
changes. The RISC allows both the constitutive maintenance of
cell identity by silencing mRNAs that are not part of the spe-
cialized cell’s repertoire as well as the holding of mRNAs of an
alternative identity in reserve (Lim et al., 2005). The environment
that cells face is many times more complex than the biological
adaptations available within the genome. Among the adaptive
responses of cells to an environmental contingency is the up-
or downregulation of proteins. The properties of miRNAs to
adjust protein levels, their dispensability under basal conditions,
their conservation, as well as the ease with which new miRNAs
appear over evolutionary time all suggest that they are suited
for environmental contingencies (Kosik, 2010). Wu et al. (2009)
have proposed that miRNAs keep the system close to the mean
and set expression boundaries of transcription factors, which are
otherwise noisy.
MicroRNA IN THE NORMAL AND PATHOLOGICAL CENTRAL
NERVOUS SYSTEM
MicroRNAs are highly expressed in the mammalian CNS, includ-
ing the spinal cord (Miska et al., 2004; Kosik, 2006; Krichevsky,
2007; Bak et al., 2008). Their expression in the spinal cord seems
to be specific and preserved through vertebrate evolution (Yunta
et al., 2012). Moreover, experimental data reveal that some miR-
NAs are cell-type specific, such as miR-124 and miR-128, which
are preferentially expressed in neurons, or miR-23 or miR-219,
which are restricted to astrocytes and oligodendrocytes, respec-
tively (Sempere et al., 2004; Smirnova et al., 2005; Lau et al., 2008).
MicroRNAs serve essential roles in virtually every aspect of CNS
function, including neurogenesis, neural development, and cellu-
lar responses leading to changes in synaptic plasticity (Krichevsky
et al., 2003; Miska et al., 2004; Sempere et al., 2004; Stefani and
Slack, 2008; Gangaraju and Lin, 2009; Li and Jin, 2010; Smith
et al., 2010; Cochella and Hobert, 2012; Goldie and Cairns, 2012).
For example, experimental overexpression or inhibition of miR-
124 have demonstrated its key role in neuronal differentiation
(Krichevsky et al., 2006; Makeyev et al., 2007; Visvanathan et al.,
2007), whereas let-7b regulates neural stem cell proliferation and
differentiation by targeting the stem cell regulator TLX and the
cell cycle regulator cyclin D1 (Zhao et al., 2010a). MicroRNAs are
also involved in the specification of glia. They have been shown to
be critical regulators of oligodendrocyte differentiation and myeli-
nation in the vertebrate CNS, in particular miR-219 and miR-338
(Zhao et al., 2010b).
In addition to their role in the development and the functioning
in the normal CNS, numerous evidences indicate that microRNA
dysregulation is implicated in a wide range of neurological dis-
eases. Several studies indicate that microRNA dysregulation can be
associated to neurodegeneration, as in Alzheimer’s disease where
the downregulation of the miR-29 cluster has been proposed to
contribute to increase BACE1 and amyloid-beta levels and thus
to the development of the disease (see Saugstad, 2010). The role
of microRNAs in neurodegeneration extends to other patholo-
gies, such as Huntington and Parkinson diseases, or even to prion
diseases (Saugstad, 2010). The evidences also suggest that microR-
NAs participate in psychiatric disorders, such as Schizophrenia,
Tourette’s syndrome, and bipolar disorder, as well as in develop-
mental disorders, such as the Rett and fragile X syndromes (Kosik,
2006; Meza-Sosa et al., 2012). MicroRNAs also participate in the
profound cellular changes that occur in the damaged CNS, where
they play an active role in the regulation of typical features of CNS
injuries, such as inflammation, apoptosis, cell proliferation, and
differentiation (see this review for SCI or Bhalala et al., 2013 for a
more general approach).
GLOBAL CHANGES IN microRNA EXPRESSION AND
REGULATION OF microRNA BIOGENESIS IN SPINAL CORD
INJURY
Several studies have analyzed microRNA expression and function
in SCI (34 published paper in August, 2013 according to PubMed).
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Seven of these studies include global analyses of microRNA expres-
sion based on microarrays. As shown in Table 1, the results from
these studies strongly vary in the resulting overall patterns, both
in the number (from as few as 10 significant expression changes
to more than 250) and profile of changing microRNAs. Much of
this variability can be ascribed to differences in SCI model, from
ischemia-reperfusion to transection, compression, or contusion,
to differences in the sampling time after injury, from 4 h to 14
days after injury, or to differences in the animal model (rats and
mice of different strains). Besides, some results from comparable
injury models and times still show strong differences. Technical
differences among platforms, laboratories, sampling and analyt-
ical procedures, etc., may account for variability in microarray
data (Git et al., 2010; Callari et al., 2012; Saugstad, 2013). In agree-
ment, we have observed that the number of significant changes
identified at 7 dpi vary from 257 to 2 depending on whether para-
metric (Student’s t-test) or non-parametric (rank product test)
tests are used (Yunta et al., 2012). However, discrepancies may
also reveal variability in microRNA expression associated to dif-
ferences in injury features. Injury severity is one of such factors.
It is well known that severity determines several aspects of the
SCI pathophysiology such as the inflammatory response or the
nerve fiber preservation/destruction (Fehlings and Tator, 1995;
Yang et al., 2005). In agreement, the expression of specific microR-
NAs (miR-129-2 and miR-146a) has been observed to correlate
with functional score after injury, an accepted proximate to SCI
severity (Strickland et al., 2011). Additional support for a severity
effect on transcription comes from mRNA data. De Biase et al.
(2005) observed strong differences in gene expression in contu-
sive injuries of different severities, with a dramatic increase in
Table 1 | Global analyses of microRNA expression after SCI.
Study SCI model miRNA expression changes
Liu et al. (2009) Animal: Sprague Dawley rats
Contusion, NYU impactor (10 g, 12.5 mm)
Level: T10
Sampling: 4 h, 1 and 7 days
4 hpo: 18 down, 23 up
1 dpo: 30 down, 27 up
7 dpo: 30 down, 30 up
Nakanishi et al. (2010) Animal: C57BL/6 mice
Compression, forceps (10 s).
Level: T11–T12
Sampling: 12 h
12 hpo: 5 down, 5 up
Strickland et al. (2011) Animal: Sprague Dawley rats
Contusion, MASCIS impactor (10 g, 12.5 mm)
Level: T12–T13
Sampling: 4 and 14 days
4 and 14 dpo: 32 down, 4 up





Yunta et al. (2012) Animal: Wistar rats
IH spinal cord impactor (200 kdynes)
Level: T8
Sampling: 1, 3, and 7 days
1 dpo: 0 down, 0 up
3 dpo: 46 down, 5 up
7 dpo: 192 down, 11 up
Hu et al. (2013b) Animal: Sprague Dawley rats
Contusion, mod. Allen Weight Drop (8 g, 40 mm)
Level: T10
Sampling: 1 and 3 days
1 dpo: 5 down, 9 up
3 dpo: 5 down, 3 up




2 dpo: 10 down, 38 up
Summary of models and results employed in published microarray analyses of miRNA expression in spinal cord injury. In all cases, data from injured animals was
compared to data from Sham injured animals. Information from several studies was very limited and we would encourage authors to submit microarray data to public
repositories as part of the process of publication, as suggested by the Microarray Gene Expression Data Society (http://www.mged.org). T, thoracic level; hpo, hours
post-operation; dpo, days post-operation; up and down indicate up- and down-regulated microRNAs.
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the number of genes with altered expression in moderate injuries
relative to mild and severe ones. Thus, injury severity could be
an important and interesting source of variation of microRNA
expression that would merit further studies. Other injury features
contribute to condition the microRNA profile of the spinal cord.
Recently, Ziu et al. (2013) have compared the expression of six
microRNAs after SCI with variable compression times showing
that the duration of compression significantly alter the expression
of different microRNAs.
Besides general variability in the microRNA expression pat-
terns, Strickland et al. (2011) and our group (Yunta et al., 2012)
observed a global downregulation of miRNA expression after a
moderate contusive injury. Interestingly, studies by De Biase et al.
(2005) and Byrnes et al. (2006) showed that moderate contu-
sive injuries present a significant bias toward gene upregulation
with a maximum at 7 days after injury, that contrast with the
more balanced numbers of up- and downregulated genes observed
in severe and mild injuries. Thus, the increase in the number
of upregulated mRNA correlates with the general decrease of
miRNA expression, which becomes particularly evident 1 week
after injury (Yunta et al., 2012). Bioinformatic analyses based on
miRNA target prediction data allowed us to show that almost
one-third of the upregulated mRNAs in De Biase et al.’s (2005)
study where targets of the downregulated microRNAs (Yunta et al.,
2012). It is tempting to hypothesize that a generalized decrease in
miRNA abundance reduces post-transcriptional regulation and
thus causes an increase in mRNA levels after moderate SCI. Two
questions immediately arise: why in moderate injuries? and, how
do injuries regulate microRNA expression or biogenesis? Although
we have no information to approach the first question, some is
available to explore the effects of injuries on microRNA biogene-
sis. MicroRNA biogenesis can be regulated at different stages. The
first layer governing miRNA abundance is the regulation of pri-
miRNA transcription by binding of transcription factors (Treiber
et al., 2012). C-Myc is one of such transcription factors, which
is known to directly upregulate miR-17-92 cluster and, at the
same time, to cause a widespread repression of microRNA expres-
sion (Chang et al., 2008). Interestingly, this transcription factor is
significantly overexpressed at 4 and 24 h following a SCI (Di Gio-
vanni et al., 2003). In agreement, the levels of several microRNAs
repressed by c-Myc in Chang et al. (2008) experiments – miR-26a,
miR-26b, miR-29a-c, miR-34a, miR-146a, miR-30a-e, let-7a, let-
7d, let-7g, miR-99b, and miR-125 – become significantly decreased
after SCI in our analysis whereas two members of the miR-17-92
cluster (miR-20a and miR-17) appear upregulated (Yunta et al.,
2012). In addition to transcriptional regulation, processing of the
pri- and pre-miRNA transcripts can be also regulated (Treiber
et al., 2012). Blockage or downregulation of key proteins in the
biogenesis pathway such Dicer, Drosha, DGCR8, or Exportin 5
leads to a reduction in the abundance of mature microRNAs and a
accumulation of pri- and pre-microRNAs (Lee et al., 2008). Exam-
ples of this regulatory pathway are common in cancer (Lu et al.,
2005) but also in other processes, such as liver regeneration after
damage (Shu et al., 2011). Little is known about the variation in
the expression and function of the microRNA biogenic machin-
ery after SCI, however, Jee et al. (2012a) have recently described a
downregulation of Dicer 7 days after contusive spinal cord. Dicer
downregulation is consistent with the observed general depletion
in miRNA abundance observed by Strickland et al. (2011) and
Yunta et al. (2012). Additionally, growth factors such as bone mor-
phogenetic proteins (BMPs) and TGF-β – overexpressed after SCI
(McTigue et al., 2000; Xiao et al., 2010) – can contribute to regulate
the microRNA biogenesis through activation of Smad proteins,
which bind to pri-miRNA and enhance their Drosha-mediated
processing to pre-miRNA (Davis et al., 2010). To what extent all
these mechanisms contribute to the different patters of microRNA
expression following SCI remains to be elucidated.
Microarray data allows identifying consistent changes in
microRNA abundance following SCI. Considering those changes
observed in at least two different studies, 36 microRNAs show con-
sistent patterns of change (see Table 2). These changes illustrate
the complexity of interpreting the microRNA expression changes
from microarray data in the SCI due to the cellular heterogene-
ity of the spinal cord and the multiple changes that take place
after injury. Expression changes in heterogeneous samples such
as the spinal cord actually correspond to the weighted mean of
the transcription programs of all cell types present in the sample
(Lu et al., 2003). Thus, the observed expression changes may result
either from changes in gene expression within a given cell type or
to changes in the relative abundance of the expressing cell types,
which severely constraints the conclusion that can be derived from
the expression data (Wang et al., 2006; Gosink et al., 2007). In fact,
heterogeneity could be a major reason why many gene expression
analyses fail a rigorous validation (Clarke et al., 2010). After injury,
the spinal cord experiences changes in the relative proportions of
different cell types due to the necrotic and apoptotic death of neu-
rons and oligodendrocytes (Grossman et al., 2001; Rowland et al.,
2008) and the infiltration of immune cells (Grossman et al., 2001;
Profyris et al., 2004). The death of specific cell types explains the
downregulation of microRNAs associated with neurons, such as
miR-124 and oligodendrocytes, miR-219 (Smirnova et al., 2005;
Lau et al., 2008). Both microRNA show a sustained decrease in
their levels that follows the progression of cell death in these neu-
ral cells. Interestingly, Liu et al. (2009) observed an increase in
miR-124 abundance during the first 4 h. A similar upregulation
was previously described in brain ischemia-reperfusion by Jeyasee-
lan et al. (2008), which proposed that such increase “indicates that
injured brain cells could be actively involved in regeneration dur-
ing the first 24 h of reperfusion.” In parallel, the infiltration of
immune and vascular cells explains the overexpression of spe-
cific microRNAs. The best characterized is miR-223, a neutrophil
microRNA (Lindsay, 2008; Sonkoly and Pivarcsi, 2009; Izumi
et al., 2011), whose upregulation reflects the infiltration of these
immune cells during the acute phase of the spinal cord (Izumi
et al., 2011; Yunta et al., 2012). Similarly, miR-451 – a red blood
cell marker (Merkerova et al., 2008) – appears clearly increased in
the first hours after injury to be later repressed or returned to con-
trol condition probably reflects the entrance of erythrocytes in the
damaged area during the acute phase and their clearance later on.
MicroRNAs IN THE REGULATION OF INFLAMMATION
FOLLOWING SCI
Spinal cord injury activates an inflammatory response that is initi-
ated by the alteration of the blood–spinal cord barrier, followed by
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Table 2 | Prominent changes in microRNA expression in murine models of spinal cord injury.
Time after injury
MicroRNA 4 h 12 h 1 days 3 days 4 days 7 days 14 days
miR-1 Up2 Up1 Down4 Down3 Up1/Down4 Down3
miR-100 Up1 Down1 Down1,4
miR-103 Up1 Down1 Down1,4
miR-107 Up1 Down1 Down1,4
miR-124 Up1 Down2 Down1 Down4 Down3 Down1,4 Down3
miR-125b-3p Down5 Down4
miR-126 Down5 Down5 Down4
miR-127 Up1 Down1 Down4 Down1,4




miR-129* Down1 Down1 Down1,4
miR-133a Up1 Up2 Down1 Down4 Down1,4
miR-133b Up1 Up2 Down1 Down4 Down1,4
miR-138 Down1 Down1 Down4 Down1,4
miR-146a Up1 Up1,4
miR-17 Up1 Up4 Up1
miR-181a Up1 Down1 Down1,4
miR-21 Up1 Up4,5 Up3 Up1,4 Down3
miR-219-2-3p Down1 Down1 Down1,4
miR-219-5p Down1 Down1 Down1,4
miR-223 Up1 Up2 Up1,4 Up4 Up3 Up1,4 Up3
miR-30b-5p Down1 Down1 Down1,4
miR-30c Down1 Down1 Down1,4
miR-30d Down1 Down1 Down1,4
miR-338* Down1 Down1 Down1,4
miR-342 Down2 Down4
miR-34a Down1 Down1 Down4 Down1,4
miR-379* Down1 Down1 Down4 Down1,4
miR-451 Up1 Up2 Down1/Up vs 7 dpo4 Down1
miR-487b Up1 Down1 Down1,4
miR-495 Down1 Down2 Down1 Down4 Down1,4
miR-708 Down5 Down4 Down4
miR-99a Up1 Down1 Down5 Down1,4
miR-let-7b Down5 Down5 Down4
The table details the changes in microRNA expression following spinal cord injury of dysregulated microRNAs according to, at least, two different studies. Data derived
from the following microarray analyses: 1Liu et al. (2009); 2Nakanishi et al. (2010); 3Strickland et al. (2011); 4Yunta et al. (2012); 5Hu et al. (2013a,b). Unless stated, Up
and Down correspond to upregulated and downregulated respect to Sham control individuals respectively.
the sequential infiltration of peripheral immune cells, the activa-
tion of the microglia and the induction of inflammatory signaling
pathways. MicroRNAs play important roles in controlling signal-
ing pathways and the dynamics of the immune response during
pathogenic immunological conditions (Lindsay, 2008; Sonkoly
and Pivarcsi, 2009; Chen et al., 2013). Following SCI, several
microRNAs undergo expression changes that can be related to
the immune response, either associated with the invading immune
cells or participating in the modulation of inflammatory pathways
(Figure 1).
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 53 | 8
Nieto-Diaz et al. MicroRNAs in spinal cord injury
FIGURE 1 | MicroRNAs in the spinal cord injury pathophysiology.
Diagram showing the cascade of processes triggered after SCI and
the contribution of differentially expressed microRNAs. Changes in
microRNA expression is indicated either as increased (up arrow) or
decreased (down arrow) after SCI. Target genes are also shown
(confirmed, direct regulation are indicated with a solid arrow,
whereas those indirect or predicted are represented with a dashed
arrow).
Immediately after the injury, the blood–spinal cord barrier
becomes disturbed and the blood immune cells infiltrate the dam-
aged area (Profyris et al., 2004; Jones et al., 2005). Early increases in
the expression of CAMs play a key role in the process of immune
cells recruitment and extravasation into the nervous tissue. Some
of these expression changes can be controlled by microRNAs. In
particular, the upregulation of VCAM1 mRNA (Aimone et al.,
2004) occurs in parallel to the downregulation of its regulator
miR-126 (Harris et al., 2008) during the first week after injury
(Yunta et al., 2012; Hu et al., 2013b). The subsequent immune cell
infiltration is responsible for several changes in the microRNA
profile of the spinal cord, as previously commented. Neutrophil
infiltration explains the upregulation of miR-223 (Lindsay, 2008;
Sonkoly and Pivarcsi, 2009; Izumi et al., 2011), whereas increased
expression of the lymphocyte specific miR-142 (Wu et al., 2007)
correlates with the access of these immune cells to the injury site
during the first week (Yunta et al., 2012). MicroRNAs are also
involved in the activation of microglia and macrophages. Par-
ticularly, the downregulation of miR-124 contributes to resting
phenotype of microglia by targeting CEBPα, a master tran-
scription factor important for the development of myeloid cells
(Ponomarev et al., 2011; Guedes et al., 2013). miR-124 shows a
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sustained downregulation after injury (Deo et al., 2006; Liu et al.,
2009; Nakanishi et al., 2010; Yunta et al., 2012) that may underlie
microglial activation. However, miR-124 is a well-characterized
neuronal microRNA and its downregulation likely reflects the
extension of neuronal death that characterizes the secondary
damage of SCI.
The inflammatory response is modulated by a number of key
molecular immune mediators, such as cytokines, chemokines
(TNF-α, IL-6, IL-1β) or the complement cascade (C1qb; Haus-
mann, 2003; Profyris et al., 2004; Jones et al., 2005), which are
known targets of microRNAs. Particularly, overexpression of three
key pro-inflammatory cytokines that modulate the inflammatory
response in the SCI is likely regulated by microRNA experiencing
expression changes after injury. Different SCI studies (Liu et al.,
2009; Yunta et al., 2012) have suggested that increasing levels of
the pro-inflammatory and pro-apoptotic factor TNF-α after injury
(Tyor et al., 2002) may result from downregulation of its regulators
miR-181 (Hutchison et al., 2013) and miR-125b (Tili et al., 2007)
after SCI (Liu et al., 2009; Yunta et al., 2012; Hu et al., 2013b).
Other microRNAs, such as miR-411, miR-99a, that appear down-
regulated after SCI (Liu et al., 2009; Yunta et al., 2012; Hu et al.,
2013b) have been also predicted to target TNF-α by bioinformat-
ics analysis. On the other hand, the increased levels of cytokine
IL-6 during the first days after injury correlate with a reduced
expression of its regulators let-7a (Iliopoulos et al., 2009) or miR-
181a (Tili et al., 2007; Iliopoulos et al., 2009). Finally, the observed
downregulation of miR-30b-5p and miR-30c during the first week
after injury (Liu et al., 2009; Yunta et al., 2012) could be related
to the overexpression of their target IL-1β. Additionally, it has
been recently described that upregulation of miR-20a induces a
cytotoxic environment with increased IL-6, TNF-α, IL-1-β, and
COX-2 expression in the spinal cord (Jee et al., 2012b) due to miR-
20a-mediated inhibition of neurogenin 1 (NGN-1). Inhibition of
this microRNA – which is upregulated after injury (Liu et al., 2009;
Jee et al., 2012b) – lead to a significant improvement in functional
recovery associated to a reduced inflammation and the increased
survival of motor neurons (Jee et al., 2012b).
Interestingly, pro-inflammatory cytokines lead to the activation
of the NF-κB signaling pathway, which is also under microR-
NAs regulation (Ma et al., 2010). In particular, downregulation
of miR-9 and miR-199 (Yunta et al., 2012) may induce the over-
expression of the NF-κB pathway genes p50NFkB and ikkb (Chen
et al., 2008; Bazzoni et al., 2009; Wang et al., 2011). The increased
expression of miR-21 may also contribute to the regulation of
this pathway but its role is less clear, as it exhibits both pro- and
anti-inflammatory effects. miR-21 targets PTEN, a negative reg-
ulator of NF-κB (Iliopoulos et al., 2010), but also PDCD4, which
promotes NF-κB activation and inhibits the expression of IL-10
(Frankel et al., 2008; Sheedy et al., 2010; Young et al., 2010). On the
opposite side, expression changes in several microRNAs that have
been observed after SCI may attenuate the activation of NF-κB
pathway, contributing to the attempts of the damaged spinal cord
to recover homeostasis (Bareyre and Schwab, 2003). These changes
include the increased expression of miR-146a at 7 days after injury
(Liu et al., 2009; Yunta et al., 2012), which negatively regulates
NF-κB expression (Taganov et al., 2006; Ma et al., 2010). Inter-
estingly, miR-146a expression is induced by NF-κB and, thus, its
overexpression at 7 days after injury may be consequence of the
increased levels of NF-κB in the previous days (Bethea et al., 1998),
forming a negative feedback that may cause the inactivation of
NF-κB pathway.
A second group of factors with a prominent role in inflamma-
tion after SCI are the complement proteins (Brennan et al., 2012).
Complement activation is involved in the removal of cellular
debris, but it may also promote clearance of mildly damaged cells
contributing to secondary cell death and demyelination. Comple-
ment protein C1qb increases its expression in the first day after
injury and persist upregulated at least 5 weeks later (Aimone et al.,
2004). C1q knockout mice show improved locomotor recovery
and reduced secondary tissue damage after contusive SCI (Galvan
et al., 2008). Interestingly, C1qb is a predicted target of miR-
103 (Perri et al., 2012), which appears downregulated in the first
week after injury (Liu et al., 2009; Yunta et al., 2012). Thus, miR-
103 downregulation could be responsible for the overexpression
of the complement protein C1qb and its associated deleterious
effects.
Inflammation is also stimulated through the inhibition of anti-
inflammatory pathways, such as the downregulation of pSMAD2,
SMAD4, and TGFBR2 by observed upregulation of members of
the miR-17-92 microRNA cluster (Mestdagh et al., 2010) or the
silencing of the anti-inflammatory neuroprotective cytokine IL-10
by miR-98, miR-106a (Sharma et al., 2009; Liu et al., 2011). Many
other microRNAs have been related to inflammation in SCI based
on in silico predictions. Bioinformatics analyses predict that anti-
inflammatory mRNAs annexin A1, annexin A2 and annexin A7
mRNAs are potential targets of the SCI, upregulated microRNAs
miR-221, miR-1, and miR-323, respectively (Liu et al., 2009; Hu
et al., 2013a). The list also includes miR-127, miR-411, and miR-
34a, significantly downregulated after SCI in adult rats and which
according to Liu et al. (2009) should lead to increased inflam-
mation. Other pro-inflammatory microRNAs, such as miR-152,
miR-214, miR-206, and miR-221, show significant changes in iso-
lated studies or even show opposite expression trend (i.e., miR-1)
in different studies (Liu et al., 2009; Strickland et al., 2011; Yunta
et al., 2012). All these results will require further assays to elucidate
the role in the inflammatory process of the SCI.
MicroRNA REGULATION OF CELL DEATH REGULATION IN SCI
Cell death is a hallmark of the pathophysiology of SCI (Crowe
et al., 1997; Liu et al., 1997). The programed cell death (apoptosis)
that characterizes the SCI secondary damage is a gene-controlled
process that is stimulated or inhibited by a variety of regulatory fac-
tors including several microRNAs (Wang, 2010). Previous studies
have shown that SCI alters the transcription levels of a substan-
tial number of genes associated with the regulation of apoptosis
(Aimone et al., 2004). The resulting scenario is complex, combin-
ing both temporal and spatial changes in the expression of both
pro and anti-apoptotic signals. In agreement, many microRNAs
have been proposed to promote or inhibit cell death during the
course of SCI, with discrepancies among microRNA expression
profiling studies. These discrepancies highlight the intricate roles
that miRNAs play in the regulation of cellular processes and the
difficulty to identify the precise activity of dysregulated microR-
NAs. However, two recent studies have provided direct evidence of
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 53 | 10
Nieto-Diaz et al. MicroRNAs in spinal cord injury
microRNAs involvement in cell death modulation following SCI
(Figure 1).
The first study deals with miR-20a, which shows an increased
expression early after injury (24 h) that persists at least for 1 week
(Liu et al., 2009; Jee et al., 2012b). miR-20a inhibits the expres-
sion of Ngn1, a protein with a key role in maintenance of cell
survival, self-renewal, and neurogenesis in normal and injured
spinal cords. Silencing Ngn1 by siNgn1 or infusion of miR-20a
into uninjured mouse spinal cord reproduced SCI-like symptoms
including apoptotic death of neural cells, whereas the administra-
tion of anti-miR-20a decreased apoptosis, reduced tissue damage
and functional deficits were significantly ameliorated (Liu et al.,
2009; Jee et al., 2012b). In a similar way, miR-486 is upregu-
lated at 7 days after injury (Jee et al., 2012a). miR-486 represses
neurogenic differentiation 6 (NeuroD6), a protein that promotes
neuronal survival by increased expression of the ROS scavenger
proteins (Jee et al., 2012a). Infusion of miR-486 into the normal
spinal cord of mice reproduces SCI symptoms including increased
neuronal death, whereas silencing miR-486 after SCI produced a
decrease in the magnitude of neuronal death and led to a signif-
icant improvement in motor recovery. Therefore upregulation of
miR-486 following SCI promotes neurodegeneration by suppress-
ing NeuroD6, pointing to this microRNA as a potential target for
therapeutic interventions (Jee et al., 2012a).
Further evidences of the roles of microRNAs on secondary cell
death come from microRNA expression changes that are accom-
panied by changes in the expression of their apoptotic gene targets.
Several pro and anti-apoptotic microRNAs act on key apoptosis
molecules, such as caspases, Fas/CD95, c-Myc, TNF-α, or mem-
bers of the BCL-2 family. For example, the decreased expression
of the let-7/miR-98 family members miR-96 and miR-146a (Liu
et al., 2009; Strickland et al., 2011; Yunta et al., 2012) would pro-
mote apoptosis by increasing the expression of their targets, the
pro-apoptotic proteins caspase 3 (Citron et al., 2000; Aimone et al.,
2004) and Fas/CD95 (Casha et al., 2001). On the contrary, over-
expression of miR-21 would protect neural cells from death by
repressing the expression of the pro-apoptotic molecules Fas lig-
and (Buller et al., 2010), TPM1 and PTEN (Hafez et al., 2012;
Han et al., 2012), and PDCD4 (Frankel et al., 2008). BCL-2 mod-
ulation is highly representative of the complexity of microRNA
regulation of cell death in SCI. Upregulation of miR-15b (Liu
et al., 2009) would decrease BCL-2 (Cimmino et al., 2005; Saito
et al., 2006) and induce apoptosis. However, upregulation of miR-
15b is counteracted by the decreased expression during the first
week of miR-138 and miR-148b, which also target BCL-2 (Liu
et al., 2009; Yunta et al., 2012). Downregulation of these microR-
NAs is broadly consistent with the increase in the number of
BCL-2-positive cells present 3 days after injury (Saito et al., 2000;
however, see Qiu et al., 2001), although microRNA downregu-
lation extends throughout the 7-day period after injury, which
is the time-point when the number of BCL-2-positive cells is
progressively reduced. Other microRNAs targeting BCL-2 appear
dysregulated after SCI. Regulation of BCL-2 by miR-107 was dis-
cussed in the profiling study by Liu et al. (2009). These authors
observed a miR-107 upregulation 4 h after injury, which they
proposed should decrease BCL-2 levels and induce apoptosis, to
be later downregulated at 7 dpi (also observed in Yunta et al.,
2012) promoting cell survival. miR-1 represents a puzzling case
that appears upregulated in Liu et al. (2009) and downregu-
lated in the analyses by Strickland et al. (2011) and Yunta et al.
(2012).
In addition to modulation of genes that regulate apoptosis,
microRNAs also participate in the disruption of the calcium
signaling or the oxidative stress events triggered after SCI that con-
tribute to secondary cell death. Expression of the gene coding for
the Ca2+-related genes such as Ca2+ pump, voltage-gated (L-type)
Ca2+ channels or Ca2+-permeable ionotropic glutamate (AMPA)
channels, is decreased with injury and post-transcriptionally regu-
lated by microRNAs. Several studies have shown that upregulated
miR-223 reduces the expression of the NR2B and GluR2 sub-
units of the NMDA and AMPA receptors, respectively (Kaur et al.,
2012). Similarly, decreased expression of voltage-gated (L-type)
Ca2+ channels may be result of upregulated miR-21 (Carrillo
et al., 2011). These could cause an increment of intracellular Ca2+
concentration level that accompanies traumatic SCI, and could
trigger mechanisms of secondary cell death, such as calpain acti-
vation. MicroRNAs also play an important role in the regulation
of oxidative stress, a hallmark of the secondary damage of SCI that
has received much attention in the attempts to develop effective
therapies (Jia et al., 2012). Recent reports have demonstrated that
miR-486 repress the expression of NeuroD6, a neuroprotective
protein that promotes the expression of ROS scavenger proteins,
such as GPX3, selenoprotein-N, and thioredoxin (Jee et al., 2012a).
Upregulation of miR-486 – observed in motor neurons at 7 days
after injury in murine models of SCI – leads to the repression of
NeuroD6 expression, and consequently to a decrease in the expres-
sion of ROS scavenger proteins and increased neurodegeneration
mediated by oxidative stress (Jee et al., 2012a).
Microarray analyses revealed increased expression of genes
associated with anti-oxidant actions, such as SOD1, SOD2, cata-
lase, and GPX (Di Giovanni et al., 2003; Aimone et al., 2004). This
overexpression of the mitochondrial SOD2 gene (sod2) 7 days
after injury (Santoscoy et al., 2002; Sugawara et al., 2002) is consis-
tent with the downregulation of its modulator miR-145 (Dharap
et al., 2009) described in Yunta et al. (2012). However, the bioinfor-
matics analysis performed by Liu et al. (2009) revealed that some
anti-oxidant genes such as SOD1 and catalase gene are poten-
tial targets of the upregulated miR-206, miR-152, and miR-214.
Moreover, it has been proposed that downregulation of miR-1
and miR-129, which regulate transcription, differentiation or pre-
vent post-mitotic cells from re-entering the cell cycle, could cause
neural cells to become aberrantly mitotic, increasing the number
of apoptotic cells observed at the injury site after SCI (Bhalala
et al., 2013).
MicroRNA MODULATION OF ASTROCYTE REACTIVITY AND
GLIAL SCAR
Astrogliosis is another hallmarks of the cellular response to SCI.
It consists in an early hypertrophic neuroprotective phase fol-
lowed by a hyperplasic phase characterized by the formation of
a dense glial scar that inhibits CNS regeneration during the sub-
acute and chronic phases of the SCI (Sofroniew, 2009). Recent
genomic analyses have shown reactive astrogliosis is associated
to a rapid, but quickly attenuated, induction of gene expression
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(Zamanian et al., 2012). Increasing evidence supports the involve-
ment of several microRNAs in the regulation of the astrocyte
response to injury, including four microRNAs that appear dys-
regulated in studies of SCI. The best characterized is miR-21. Its
expression increases in a time-dependent manner following SCI
(Liu et al., 2009; Bhalala et al., 2012; Yunta et al., 2012; Hu et al.,
2013b) and is highly expressed in astrocytes during the chronic
stage (Bhalala et al., 2012). miR-21 expression after SCI shows a
marked spatial pattern, with highest expression in the astrocytes
adjacent to the lesion area (Bhalala et al., 2012). The role of miR-
21 in astrogliosis has been studied in detail using transgenic mice
that overexpress in astrocytes either miR-21 or a miRNA sponge
designed to inhibit miR-21 function (Bhalala et al., 2012). The
results from these studies demonstrate that miR-21 overexpres-
sion in astrocytes abrogates the hypertrophic astrocytic response
after severe SCI, which is consistent with previous studies in vitro
(Sahni et al., 2010; Sayed and Abdellatif, 2011). On the contrary,
miR-21 inhibition enhances the hypertrophic response in early
and chronic stages after SCI (Bhalala et al., 2012). BMP signal-
ing following SCI mediates the miR-21 and astrocytic response
through the opposing effects of the BMP receptors BMPR1a and
BMPR1b (Sahni et al., 2010). BMPR1a signaling decreases levels
of miR-21 and induces reactive astrocytic hypertrophy, whereas
BMPR1b signaling increases miR-21 levels and negatively regu-
lates astrogliosis. These findings point to the BMP–BMPR–miR-21
axis as a key regulator of astrocytic hypertrophy and glial scar
progression after SCI, modulating the pro-reactive effects of the
inflammatory signaling.
A second microRNA that has been related to astrogliosis is
miR-125b. Overexpression of miR-125b correlates with the over-
expression of the astrogliosis markers GFAP and vimentin in
several neurological disorders (Pogue et al., 2010). In vitro studies
show that miR-125b downregulation in IL-6 stimulated reactive
astrocytes increases the expression of its target cyclin-dependent
kinase inhibitor 2A (CDKN2A), a negative regulator cell growth,
and attenuates cell proliferation. Thus, evidences indicate that
miRNA-125b upregulation contributes to astrogliosis. However,
contrary to expectations, miR-125b appears downregulated dur-
ing the first week after injury (Yunta et al., 2012), which would
contribute to inhibit astrocyte proliferation and astrogliosis.
The miR-181 family of miRNAs is another candidate for post-
transcriptional regulation of neuroinflammation and reactive glio-
sis (Hutchison et al., 2013). miR-181s are constitutively expressed
in astrocytes but inflammation causes its downregulation, in
agreement with in vivo observations following SCI (Liu et al., 2009;
Yunta et al., 2012). Genetic studies demonstrated that miR-181
inhibits the production of multiple pro-inflammatory cytokines
(TNF-α, IL-6, IL-1β, IL-8, LIF, and HMGB1) and increases the
levels of the anti-inflammatory cytokine IL-10 (Hutchison et al.,
2013) in cultured astrocytes under LPS inflammatory exposure.
Thus, miR-181s act as negative regulators of astrogliosis, reducing
the expression of reactivity promoters such as pro-inflammatory
cytokines (Balasingam et al., 1994; Sofroniew, 2009) and FGF2
(Goddard et al., 2002), and increasing the expression of reactivity
inhibitors, such as IL-10 (Balasingam and Yong, 1996).
Similarly to miR-181s, miR-146a is a negative regulator of
the astrocyte response to inflammation and, consequently, a
negative regulator of astrogliosis (Iyer et al., 2012). miR-146a is
expressed in reactive astrocytes in the areas of prominent glio-
sis (Iyer et al., 2012), and appears upregulated 7 dpi after SCI
(Liu et al., 2009; Strickland et al., 2011; Yunta et al., 2012) as
well as in several neurodegenerative pathologies (Junker et al.,
2009; Cui et al., 2010; Iyer et al., 2012). Studies with astroglioma
cell lines and primary astrocytes have shown that IL-1β stimula-
tion induces a prominent upregulation of miR-146a expression.
Overexpression of miR-146a has anti-inflammatory effects and
significantly reduces the expression of signaling molecules down-
stream IL-1β, such as IRAK-1, IRAK-2, and TRAF-6 and inhibits
the release of pro-reactive and pro-inflammatory factors, includ-
ing IL-6 and COX-2 (Iyer et al., 2012). Thus, miR-146a forms a
negative feedback of the IL-1β signaling, being induced by IL-1β
but blocking the expression of its downstream response. Overex-
pression of miR-146a following SCI adds to the overexpression
of miR-21 and miR-125b to limit astrocyte reactivity. On the
contrary, downregulation of miR-181 family members would pro-
mote astrocyte reactivity, indicating a fairly complex regulation
of the astrocyte response. It is interesting to note that accord-
ing to recent studies, the disruption of microRNA biogenesis
by deletion of Dicer leads to an altered mature astroglial tran-
scriptome signature that resembles to a reactive state (Tao et al.,
2011), which adds a further layer of complexity to the whole
picture.
THE ROLES OF microRNAs IN AXONAL REGENERATION,
MYELINATION, AND OTHER PROCESSES
Although less studied, microRNAs also seem to contribute to
the regulation of other pivotal processes in the SCI pathophys-
iology, such as axonal regeneration, remyelination, or pain. As
we mentioned before, failure to produce a sustained regenera-
tive response is one of the critical features of the CNS. Local
environmental clues are largely responsible for the lack of regen-
eration but intracellular specific features associated to neural cell
maturation are also involved (see, for example, Goldberg, 2003).
Different evidences indicate that microRNAs can contribute to
these changes. In fact, microRNAs have a critical role in neu-
rite outgrowth in post-mitotic neurons as demonstrated in Dicer
conditional knockout mice. In this animals, silencing of Dicer
and the subsequent inhibition of the microRNA biogenesis causes
defects in neurite outgrowth and decreased soma size but has
not influence in neurogenesis, cortical patterning or cell sur-
vival (Hong et al., 2013). Additional evidences have been obtained
from the zebrafish, a model of spontaneous axonal regenera-
tion in the damaged spinal cord (Becker et al., 1997). In this
fish, miR-133b is overexpressed in regenerating neurons follow-
ing SCI and its inhibition using antisense morpholinos result
in reduced axonal regeneration (Yu et al., 2011). Functionally,
miR-133b contributes to spinal cord regeneration through the
downregulation of its target RhoA, a small GTPase that inhibits
axonal growth. Contrary to zebrafish, miR-133b shows a sig-
nificant downregulation at 1 and 7 days after contusive SCI in
mammals (Liu et al., 2009; Yunta et al., 2012), which may con-
tribute to their reduced neuroregenerative capacity. miRNA-124
presents a somehow similar behavior that may also contribute
to reduce axonal regeneration after SCI. Previous studies have
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shown that miR-124 overexpression in differentiating mouse
P19 cells promotes neurite outgrowth, while miR-124 inhibition
reduces it (Yu et al., 2008). Thus the observed miR-124 down-
regulation after SCI may also contribute to hinder the axonal
regenerative capacities of spinal cord neurons. However, microR-
NAs may also contribute to the activation of pro-regenerative
gene programs after injury. Di Giovanni et al. (2005a) described
the overexpression at 7 and 28 days after SCI of a gene clus-
ter that comprise known promoters of the neural plasticity and
the neurite outgrowth, including synaptotagmin-1. Interestingly,
synaptotagmin-1 is a target of miR-34a (Agostini et al., 2011), and
its upregulation after SCI is consistent with the observed downreg-
ulation of miR-34a at 3 and 7 after injury (Liu et al., 2009; Yunta
et al., 2012).
The progressive loss of myelin in the areas surrounding the
injury is another critical feature of the SCI that results from the
combined effects of damage to oligodendrocytes and remyeli-
nation failure. Evidences have confirmed that microRNA loss
of function due to Dicer1 ablation in mature oligodendrocytes
causes demyelination, gliosis, and neuronal degeneration (Shin
et al., 2009; Dugas et al., 2010). More precisely, Shin et al. (2009)
identified miR-219 as a central actor in myelin maintenance and
remyelination. miR-219 is highly expressed in mature oligoden-
drocytes and when is lost due to Dicer1 ablation, miR-219 target
ELOVL7 increases its expression resulting in lipid accumulation in
myelin-rich areas and disrupting the stability of the membranes
(Shin et al., 2009). Strikingly, miR-219 abundance is markedly
reduced after SCI (Liu et al., 2009; Yunta et al., 2012) although
this decrease may also reflect the loss of spinal cord oligodendro-
cytes that takes place after injury. Further studies are needed to
determine the contribution of microRNAs in demyelination and
remyelination and to evaluate their use as therapeutic tools in the
SCI and other CNS pathologies.
In addition to their direct roles in most processes impli-
cated in the pathophysiology of the SCI, microRNAs are also
involved in the functional consequences of SCI, including the
neuropathic pain. Neuropathic pain is the manifestation of mal-
adaptive plasticity in the nervous system characterized by pain
in the absence of a stimulus and reduced nociceptive thresholds
(Scholz and Woolf, 2007). It is a debilitating accompaniment
of SCI that affects up to 50% SCI patients and limit their abil-
ity to achieve an optimal level of activity (Mann et al., 2013).
Plastic changes in sensory neuron excitability are considered the
cellular basis of neuropathic pain, although a growing body of
evidence also implicates activated microglia and astrocytes as key
players in the development of pain (Scholz and Woolf, 2007).
Although information on the roles of miRNAs in neuropathic
pain following SCI is very restricted, available evidences indi-
cate that microRNAs expression at the spinal cord respond to
pain induction (Kusuda et al., 2011; Genda et al., 2013; Li et al.,
2013), although evidences are sometimes contradictory (Branden-
burger et al., 2012). There are also evidences of the contribution
of microRNAs in the development of central neuropathic pain.
Recently, Im et al. (2012) demonstrated that SCI reduced the
expression of miR-23b in GABAergic neurons from the spinal
cord while increasing the levels of NADPH oxidase 4 (NOX4),
a target of miR-23b and a key factor in the production of ROS
and pain induction. Reduction of NOX4 expression and neuro-
pathic pain was observed after infusion of miR-23b to the spinal
cord confirming the involvement of this microRNA in pain regula-
tion. Similarly, intrathecal administration of miR-124 inhibits the
activation of spinal cord microglia, reducing inflammation and
preventing neuropathic pain (Willemen et al., 2012). Many other
microRNAs have been described to affect neuropathic pain at dif-
ferent levels, particularly at the dorsal root ganglia. However, a
review of this complex system lies beyond the scope of the present
article.
CLINICAL APPLICATIONS: microRNA-BASED THERAPEUTIC
AND DIAGNOSTIC TOOLS
The capability of individual microRNAs to reduce the expres-
sion of numerous components of cellular networks supposes an
opportunity to modulate the cell phenotypes by manipulating the
expression or function of microRNAs. The possibility of a thera-
peutic use of the miRNAs is highly appealing due to their capability
to modulate entire gene programs though tuning, not blunting, the
expression of their targets (Hydbring and Badalian-Very, 2013).
Moreover, microRNA deregulation has a critical role in a wide
range of pathologies, and, indeed, several studies have identified
specific deregulated microRNAs that can constitute potential tar-
gets of therapeutic approaches in a wide range of pathologies. As
a consequence, in the short time from its discovery in humans, a
microRNA-based therapeutic for suppression of hepatitis C virus
has already entered phase II clinical trial and several others are on
their way (see review in Hydbring and Badalian-Very, 2013).
Therapeutic approaches are based on local or systemic admin-
istration of either antagonists (anti-miRs) of endogenous microR-
NAs that show a gain-of-function in diseased tissues or mimics that
replace downregulated microRNAs. Both modulators incorporate
chemical modifications (phosphorothionate backbones, locked
nucleic acids or LNAs, etc.) to confer resistance to nucleases,
increase stability during delivery, and facilitate cellular uptake.
Anti-miRs are siRNAs designed to inhibit miRNAs through com-
plementary base pairing, in a similar way to siRNA. Since binding
is irreversible, the resulting miRNA duplex cannot be processed
by RISC and/or degraded. Anti-miRs are synthesized as short
single-stranded oligonucleotides of small size that make delivery
possible without vehicle-systems. On the contrary, administra-
tion of microRNA mimics, also known as “miRNA replacement
therapy,” aims to re-introduce miRNAs into diseased cells that are
normally expressed in healthy cells. miRNA mimics is expected
to re-activate pathways required for normal cellular welfare and
block those driving disease. To be processed correctly by the cellu-
lar RNAi-machinery, miRNA mimics need to be double-stranded,
which confer them greater chemical complexity and larger size.
Thus, miRNA mimics require delivery techniques similar to those
employed in siRNA therapeutics, including microvesicles, exo-
somes or adeno-associated viruses, which increase the complexity
of replacement therapies.
The critical contribution of the phenotypic changes in the neu-
ral, immune, and vascular cells in the pathophysiology of the SCI
and the capabilities of miRNAs to modulate these changes (see
previous sections) make miRNA therapeutics a highly promising
approach to be explored. Although no microRNA-based therapy
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has entered clinical trials for SCI up to now, preclinical assays pro-
vide the necessary proof of concept. Experimental treatments with
anti-miRs have demonstrated that inhibition of specific dysregu-
lated microRNAs back to pre-injury levels can effectively reduce
cell death. For example, Jee et al. (2012b) showed that local infu-
sion of miR-20a inhibitor in the injured spinal cord reduced the
expression of pro-apoptotic genes, and promoted neuron sur-
vival and functional recovery. Similarly, Hu et al. (2013b) also
employed microRNA inhibition to explore the neuroprotective
role of miR-21. Intrathecal infusion of miR-21 antagomir resulted
in over-expression of pro-apoptotic genes, increased cell death
and reduced recovery of the hindlimb motor function. On the
other hand, two articles have proven that miRNA replacement
can be also a viable therapeutic approach. Willemen et al. (2012)
showed that intrathecal administration of miR-124 prevents per-
sistent pain in rats, probably due to its modulation of microglial
activation (Ponomarev et al., 2011). Im et al. (2012) reported sim-
ilar results infusing miR-23b intrathecally to a murine model of
neuropathic pain. According to these authors, restoring the nor-
mal levels of miR-23b reduced the expression of inflammatory
proteins, particularly NOX4 in GABAergic neurons, protecting
them from cell death, and ameliorating the neuropathic pain
derived from SCI. These preclinical data strongly supports the
feasibility of microRNA-based therapeutics in SCI treatment,
although key aspects –including timing and side effects – remain
to be elucidated. Detailed analysis characterizing the beneficial
effects and determining the underlying mechanisms are strongly
needed before microRNAs can reach the clinic in the treatment of
the SCI.
Another clinically relevant but yet unexplored topic con-
cerns how SCI alters the profiles of circulating microRNAs, and
how information on these alterations can be used for diagnos-
tic and prognostic purposes. Circulating or cell-free microRNAs
are released to the body fluids either actively by secretion in
exosomes or microvesicles or in association with RNA-binding
proteins such as AGO2 and HDL; or passively, within apoptotic
bodies liberated from dying cells (Chen et al., 2012; Zampetaki
and Mayr, 2012). Encapsulation within lipid vesicles or asso-
ciation to binding proteins confers high stability to circulating
microRNAs, despite the presence of large amounts of RNase in
the body fluids (Chen et al., 2012; Li et al., 2012). Stability of
circulating microRNAs together with the changes in microRNA
expression in pathological states make circulating microRNAs
promising biomarkers. In fact, since their discovery in all body
fluids in 2008, nearly 500 articles have proposed several circulat-
ing microRNAs as biomarkers for different pathologies, including
cancer, cardiovascular pathologies, and CNS injuries, among oth-
ers (Laterza et al., 2009; Kosaka et al., 2010; Zhang et al., 2011;
Pritchard et al., 2012). For example, analysis of the expression
of circulating microRNAs after a traumatic brain injury has
identified several potential biomarkers in humans (Redell et al.,
2010) and rats (Balakathiresan et al., 2012). Also, it has been
shown that the plasma concentration of neuron marker miR-
124 becomes significantly increased after acute stroke (Laterza
et al., 2009). However, quantification of circulating microRNAs
can be challenging due to (i) their low concentrations, (ii) the
effects of cell contaminants, and iii) the absence of endogenous
controls for normalization. Low concentrations of circulating
microRNAs suppose a technical challenge for microRNA extrac-
tion and quantification, and also increase the risk that microRNAs
from contaminant cells, which are at much higher concentra-
tions, would mask or confound the circulating microRNA profile
(Kirschner et al., 2011).
Circulating microRNAs are also highly interesting due to their
possible role as paracrine regulators. Circulating microRNAs can
be transferred to neighboring or distant cells, altering the expres-
sion of target genes and regulating various functions, including
proliferation, death or even tumor cell invasion (see Zhu and Fan,
2011, and references therein). Interestingly, microRNA transfer
occurs when microRNAs are wrapped in exosomes, microvesi-
cles, or apoptotic bodies, as well as when packaged with proteins
(Zhu and Fan, 2011). Although most available evidence deals with
circulating microRNA transfer in immune and vascular cells, a
recent article has also demonstrated that miRNA transfer occurs
between neural cells. According to Morel et al. (2013), neurons are
able to secrete exosomes containing miR-124a, which are internal-
ized by astrocytes causing an increase in the glutamate transporter
GLT1.
CONCLUDING REMARKS
Spinal cord injury is a complex pathology that induces strong cel-
lular and molecular changes in the nervous, immune, and vascular
systems. These changes alter the expression of the microRNAs -
small non-coding RNAs that post-transcriptionally regulate the
expression of thousands of genes- to different degrees up to a gen-
eral downregulation of the microRNA expression. Bioinformatic
analyses of the microRNA and mRNA expression profiles in the
injured spinal cord have predicted that microRNA dysregulation
strongly affects processes developing after the SCI. However, much
more research analyzing the expression of specific cell popula-
tions and evaluating the effects of microRNA dysregulation is still
needed if we want to validate the bioinformatic predictions, and to
precisely characterize the changes in microRNA expression after
SCI as well as their causes and their functional consequences. The
pioneering studies developed up to now have been able to demon-
strate the active role of individual microRNAs in the regulation
of key processes of the SCI, such as cell death, inflammation, and
astrogliosis. These results strongly suggest that microRNAs can
be highly valuable therapeutic targets to modulate the deleteri-
ous events that follow SCI and to promote regenerative responses
that will contribute to reduce the functional deficits associated to
the SCI.
AUTHOR CONTRIBUTIONS
All authors contributed in the conception and design of the present
review, as well as in drafting and revising the manuscript. All
authors have given full approval to the present version for its
publication.
ACKNOWLEDGMENTS
We would like to thank Dr. Tommaso Pizzorusso for the invita-
tion to contribute to the present volume, and to two anonymous
reviewers for their useful comments. Present contribution has
been funded by Instituto de Salud Carlos III (MINECO), PI
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 53 | 14
Nieto-Diaz et al. MicroRNAs in spinal cord injury
12/28282. Rosa Navarro-Ruiz is funded by FISCAM (grant PI
2010/19) and Ángela del Águila by La Marato de TV3 foundation
(grant exp.112131).
REFERENCES
Agostini, M., Tucci, P., Steinert, J. R., Shalom-Feuerstein, R., Rouleau, M.,
Aberdam, D., et al. (2011). microRNA-34a regulates neurite outgrowth, spinal
morphology, and function. Proc. Natl. Acad. Sci. U.S.A. 108, 21099–21104. doi:
10.1073/pnas.1112063108
Aimone, J. B., Leasure, J. L., Perreau, V. M., and Thallmair, M. (2004). Spatial and
temporal gene expression profiling of the contused rat spinal cord. Exp. Neurol.
189, 204–221. doi: 10.1016/j.expneurol.2004.05.042
Baek, D., Villen, J., Shin, C., Camargo, F. D., Gygi, S. P., and Bartel, D. P.
(2008). The impact of microRNAs on protein output. Nature 455, 64–71. doi:
10.1038/nature07242
Bak, M., Silahtaroglu, A., Moller, M., Christensen, M., Rath, M. F., Skryabin, B., et al.
(2008). MicroRNA expression in the adult mouse central nervous system. RNA
14, 432–444. doi: 10.1261/rna.783108
Balakathiresan, N., Bhomia, M., Chandran, R., Chavko, M., McCarron, R. M., and
Maheshwari, R. K. (2012). MicroRNA let-7i is a promising serum biomarker
for blast-induced traumatic brain injury. J. Neurotrauma 29, 1379–1387. doi:
10.1089/neu.2011.2146
Balasingam, V., Tejada-Berges, T., Wright, E., Bouckova, R., and Yong, V. W. (1994).
Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines.
J. Neurosci. 14, 846–856.
Balasingam, V., and Yong, V. W. (1996). Attenuation of astroglial reactivity by
interleukin-10. J. Neurosci. 16, 2945–2955.
Bareyre, F. M., and Schwab, M. E. (2003). Inflammation, degeneration and regener-
ation in the injured spinal cord: insights from DNA microarrays. Trends Neurosci.
26, 555–563. doi: 10.1016/j.tins.2003.08.004
Bazzoni, F., Rossato, M., Fabbri, M., Gaudiosi, D., Mirolo, M., Mori, L., et al.
(2009). Induction and regulatory function of miR-9 in human monocytes and
neutrophils exposed to proinflammatory signals. Proc. Natl. Acad. Sci. U.S.A. 106,
5282–5287. doi: 10.1073/pnas.0810909106
Beck, K. D., Nguyen, H. X., Galvan, M. D., Salazar, D. L., Woodruff, T. M., and
Anderson, A. J. (2010). Quantitative analysis of cellular inflammation after trau-
matic spinal cord injury: evidence for a multiphasic inflammatory response
in the acute to chronic environment. Brain 133, 433–447. doi: 10.1093/brain/
awp322
Becker, T., Wullimann, M. F., Becker, C. G., Bernhardt, R. R., and Schachner, M.
(1997). Axonal regrowth after spinal cord transection in adult zebrafish. J. Comp.
Neurol. 377, 577–595. doi: 10.1002/(SICI)1096-9861(19970127)377:4<577::AID-
CNE8>3.0.CO;2-#
Bethea, J. R., Castro, M., Keane, R. W., Lee, T. T., Dietrich, W. D., and Yezierski,
R. P. (1998). Traumatic spinal cord injury induces nuclear factor-κB activation.
J. Neurosci. 18, 3251–3260.
Bhalala, O. G., Pan, L., Sahni, V., McGuire, T. L., Gruner, K., Tourtellotte, W. G., et al.
(2012). microRNA-21 regulates astrocytic response following spinal cord injury.
J. Neurosci. 32, 17935–17947. doi: 10.1523/JNEUROSCI.3860-12.2012
Bhalala, O. G., Srikanth, M., and Kessler, J. A. (2013). The emerging roles of microR-
NAs in CNS injuries. Nat. Rev. Neurol. 9, 328–339. doi: 10.1038/nrneurol.2013.67
Biering-Sorensen, E., Pedersen, V., and Clausen, S. (1990). Epidemiology of spinal
cord lesions in Denmark. Paraplegia 28, 105–118. doi: 10.1038/sc.1990.13
Brandenburger, T., Castoldi, M., Brendel, M., Grievink, H., Schlosser, L.,
Werdehausen, R., et al. (2012). Expression of spinal cord microRNAs in a
rat model of chronic neuropathic pain. Neurosci. Lett. 506, 281–286. doi:
10.1016/j.neulet.2011.11.023
Brennan, F. H., Anderson, A. J., Taylor, S. M., Woodruff, T. M., and Ruitenberg, M.
J. (2012). Complement activation in the injured central nervous system: another
dual-edged sword? J. Neuroinflammation 9, 137. doi: 10.1186/1742-2094-9-137
Buller, B., Liu, X., Wang, X., Zhang, R. L., Zhang, L., Hozeska-Solgot, A., et al. (2010).
MicroRNA-21 protects neurons from ischemic death. FEBS J. 277, 4299–4307.
doi: 10.1111/j.1742-4658.2010.07818.x
Byrnes, K. R., Garay, J., Di Giovanni, S., De Biase, A., Knoblach, S. M., Hoffman,
E. P., et al. (2006). Expression of two temporally distinct microglia-related gene
clusters after spinal cord injury. Glia 53, 420–433. doi: 10.1002/glia.20295
Callari, M., Dugo, M., Musella, V., Marchesi, E., Chiorino, G., Grand, M. M.,
et al. (2012). Comparison of microarray platforms for measuring differential
microRNA expression in paired normal/cancer colon tissues. PLoS ONE 7:e45105.
doi: 10.1371/journal.pone.0045105
Carmel, J. B., Galante, A., Soteropoulos, P., Tolias, P., Recce, M., Young, W., et al.
(2001). Gene expression profiling of acute spinal cord injury reveals spreading
inflammatory signals and neuron loss. Physiol. Genomics 7, 201–213.
Carrillo, E. D., Escobar, Y., Gonzalez, G., Hernandez, A., Galindo, J. M., Garcia, M.
C., et al. (2011). Posttranscriptional regulation of the β2-subunit of cardiac L-
type Ca2+ channels by MicroRNAs during long-term exposure to isoproterenol in
rats. J. Cardiovasc. Pharmacol. 58, 470–478. doi: 10.1097/FJC.0b013e31822a789b
Casha, S., Yu, W. R., and Fehlings, M. G. (2001). Oligodendroglial apoptosis occurs
along degenerating axons and is associated with FAS and p75 expression following
spinal cord injury in the rat. Neuroscience 103, 203–218. doi: 10.1016/S0306-
4522(00)00538-8
Chamankhah, M., Eftekharpour, E., Karimi-Abdolrezaee, S., Boutros, P. C., San-
Marina, S., and Fehlings, M. G. (2013). Genome-wide gene expression profiling
of stress response in a spinal cord clip compression injury model. BMC Genomics
14:583. doi: 10.1186/1471-2164-14-583
Chang, T. C., Yu, D., Lee, Y. S., Wentzel, E. A., Arking, D. E., West, K. M., et al.
(2008). Widespread microRNA repression by Myc contributes to tumorigenesis.
Nat. Genet. 40, 43–50. doi: 10.1038/ng.2007.30
Chen, C. Z., Schaffert, S., Fragoso, R., and Loh, C. (2013). Regulation of immune
responses and tolerance: the microRNA perspective. Immunol. Rev. 253, 112–128.
doi: 10.1111/imr.12060
Chen, R., Alvero, A. B., Silasi, D. A., Kelly, M. G., Fest, S., Visintin, I., et al. (2008).
Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells.
Oncogene 27, 4712–4723. doi: 10.1038/onc.2008.112
Chen, X., Liang, H., Zhang, J., Zen, K., and Zhang, C. Y. (2012). Secreted microRNAs:
a new form of intercellular communication. Trends Cell Biol. 22, 125–132. doi:
10.1016/j.tcb.2011.12.001
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., et al.
(2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad.
Sci. U.S.A. 102, 13944–1399. doi: 10.1073/pnas.0506654102
Citron, B. A., Arnold, P. M., Sebastian, C., Qin, F., Malladi, S., Ameenuddin, S., et al.
(2000). Rapid upregulation of caspase-3 in rat spinal cord after injury: mRNA,
protein, and cellular localization correlates with apoptotic cell death. Exp. Neurol.
166, 213–226. doi: 10.1006/exnr.2000.7523
Clarke, J., Seo, P., and Clarke, B. (2010). Statistical expression deconvolution from
mixed tissue samples. Bioinformatics 26, 1043–1049. doi: 10.1093/bioinformat-
ics/btq097
Cochella, L., and Hobert, O. (2012). Diverse functions of microRNAs in nervous
system development. Curr. Top. Dev. Biol. 99, 115–143. doi: 10.1016/B978-0-12-
387038-4.00005-7
Crowe, M. J., Bresnahan, J. C., Shuman, S. L., Masters, J. N., and Beattie, M. S.
(1997). Apoptosis and delayed degeneration after spinal cord injury in rats and
monkeys. Nat. Med. 3, 73–76. doi: 10.1038/nm0197-73
Cui, J. G., Li, Y. Y., Zhao, Y., Bhattacharjee, S., and Lukiw, W. J. (2010).
Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1)
and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial
cells and in Alzheimer disease. J. Biol. Chem. 285, 38951–38960. doi:
10.1074/jbc.M110.178848
David, S., and Aguayo, A. J. (1981). Axonal elongation into peripheral nervous
system “bridges” after central nervous system injury in adult rats. Science 214,
931–933. doi: 10.1126/science.6171034
Davis, B. N., Hilyard, A. C., Nguyen, P. H., Lagna, G., and Hata, A. (2010). Smad
proteins bind a conserved RNA sequence to promote microRNA maturation by
Drosha. Mol. Cell 39, 373–384. doi: 10.1016/j.molcel.2010.07.011
De Biase, A., Knoblach, S. M., Di Giovanni, S., Fan, C., Molon, A., Hoff-
man, E. P., et al. (2005). Gene expression profiling of experimental trau-
matic spinal cord injury as a function of distance from impact site and
injury severity. Physiol. Genomics 22, 368–381. doi: 10.1152/physiolgenomics.
00081.2005
Deo, M., Yu, J. Y., Chung, K. H., Tippens, M., and Turner, D. L. (2006). Detec-
tion of mammalian microRNA expression by in situ hybridization with RNA
oligonucleotides. Dev. Dyn. 235, 2538–2548. doi: 10.1002/dvdy.20847
Dharap, A., Bowen, K., Place, R., Li, L. C., and Vemuganti, R. (2009). Transient
focal ischemia induces extensive temporal changes in rat cerebral microRNAome.
J. Cereb. Blood Flow Metab. 29, 675–687. doi: 10.1038/jcbfm.2008.157
Di Giovanni, S., De Biase, A., Yakovlev, A., Finn, T., Beers, J., Hoffman, E. P.,
et al. (2005a). In vivo and in vitro characterization of novel neuronal plasticity
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 53 | 15
Nieto-Diaz et al. MicroRNAs in spinal cord injury
factors identified following spinal cord injury. J. Biol. Chem. 280, 2084–2091. doi:
10.1074/jbc.M411975200
Di Giovanni, S., Faden, A. I., Yakovlev, A., Duke-Cohan, J. S., Finn, T., Thouin, M.,
et al. (2005b). Neuronal plasticity after spinal cord injury: identification of a gene
cluster driving neurite outgrowth. FASEB J. 19, 153–154.
Di Giovanni, S., Knoblach, S. M., Brandoli, C., Aden, S. A., Hoffman, E. P., and
Faden, A. I. (2003). Gene profiling in spinal cord injury shows role of cell cycle in
neuronal death. Ann. Neurol. 53, 454–468. doi: 10.1002/ana.10472
Donnelly, D. J., and Popovich, P. G. (2008). Inflammation and its role in neuropro-
tection, axonal regeneration and functional recovery after spinal cord injury. Exp.
Neurol. 209, 378–388. doi: 10.1016/j.expneurol.2007.06.009
Dugas, J. C., Cuellar, T. L., Scholze, A., Ason, B., Ibrahim, A., Emery, B., et al. (2010).
Dicer1 and miR-219 Are required for normal oligodendrocyte differentiation and
myelination. Neuron 65, 597–611. doi: 10.1016/j.neuron.2010.01.027
Dumont, R. J., Okonkwo, D. O., Verma, S., Hurlbert, R. J., Boulos, P. T., Ellegala,
D. B., et al. (2001). Acute spinal cord injury, part I: pathophysiologic mecha-
nisms. Clin. Neuropharmacol. 24, 254–264. doi: 10.1097/00002826-200109000-
00002
Ebert, M. S., and Sharp, P. A. (2012). Roles for microRNAs in conferring robustness
to biological processes. Cell 149, 515–524. doi: 10.1016/j.cell.2012.04.005
Faulkner, J. R., Herrmann, J. E., Woo, M. J., Tansey, K. E., Doan, N. B., and Sofroniew,
M. V. (2004). Reactive astrocytes protect tissue and preserve function after
spinal cord injury. J. Neurosci. 24, 2143–2155. doi: 10.1523/JNEUROSCI.3547-
03.2004
Fawcett, J. W., and Asher, R. A. (1999). The glial scar and central nervous system
repair. Brain Res. Bull. 49, 377–391. doi: 10.1016/S0361-9230(99)00072-6
Fehlings, M. G., and Tator, C. H. (1995). The relationships among the severity of
spinal cord injury, residual neurological function, axon counts, and counts of
retrogradely labeled neurons after experimental spinal cord injury. Exp. Neurol.
132, 220–228. doi: 10.1016/0014-4886(95)90027-6
Fleming, J. C., Norenberg, M. D., Ramsay, D. A., Dekaban, G. A., Marcillo, A. E.,
Saenz, A. D., et al. (2006). The cellular inflammatory response in human spinal
cords after injury. Brain 129, 3249–3269. doi: 10.1093/brain/awl296
Frankel, L. B., Christoffersen, N. R., Jacobsen, A., Lindow, M., Krogh, A., and Lund,
A. H. (2008). Programmed cell death 4 (PDCD4) is an important functional target
of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 283, 1026–1033.
doi: 10.1074/jbc.M707224200
Friedman, R. C., Farh, K. K., Burge, C. B., and Bartel, D. P. (2009). Most mam-
malian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92–105.
doi: 10.1101/gr.082701.108
Galvan, M. D., Luchetti, S., Burgos, A. M., Nguyen, H. X., Hooshmand, M. J.,
Hamers, F. P., et al. (2008). Deficiency in complement C1q improves histological
and functional locomotor outcome after spinal cord injury. J. Neurosci. 28, 13876–
13888. doi: 10.1523/JNEUROSCI.2823-08.2008
Gangaraju, V. K., and Lin, H. (2009). MicroRNAs: key regulators of stem cells. Nat.
Rev. Mol. Cell Biol. 10, 116–125. doi: 10.1038/nrm2621
Genda, Y., Arai, M., Ishikawa, M., Tanaka, S., Okabe, T., and Sakamoto, A. (2013).
microRNA changes in the dorsal horn of the spinal cord of rats with chronic
constriction injury: a TaqMan(R) Low Density Array study. Int. J. Mol. Med. 31,
129–137. doi: 10.3892/ijmm.2012.1163
Git, A., Dvinge, H., Salmon-Divon, M., Osborne, M., Kutter, C., Hadfield, J.,
et al. (2010). Systematic comparison of microarray profiling, real-time PCR, and
next-generation sequencing technologies for measuring differential microRNA
expression. RNA 16, 991–1006. doi: 10.1261/rna.1947110
Goddard, D. R., Berry, M., Kirvell, S. L., and Butt, A. M. (2002). Fibroblast growth
factor-2 induces astroglial and microglial reactivity in vivo. J. Anat. 200, 57–67.
doi: 10.1046/j.0021-8782.2001.00002.x
Goldberg, J. L. (2003). How does an axon grow? Genes Dev. 17, 941–958. doi:
10.1101/gad.1062303
Goldie, B. J., and Cairns, M. J. (2012). Post-transcriptional trafficking and regulation
of neuronal gene expression. Mol. Neurobiol. 45, 99–108. doi: 10.1007/s12035-
011-8222-0
Gosink, M. M., Petrie, H. T., and Tsinoremas, N. F. (2007). Electronically subtracting
expression patterns from a mixed cell population. Bioinformatics 23, 3328–3334.
doi: 10.1093/bioinformatics/btm508
Grossman, S. D., Rosenberg, L. J., and Wrathall, J. R. (2001). Temporal-spatial
pattern of acute neuronal and glial loss after spinal cord contusion. Exp. Neurol.
168, 273–282. doi: 10.1006/exnr.2001.7628
Guedes, J., Cardoso, A. L., and Pedroso de Lima, M. C. (2013). Involvement of
microRNA in microglia-mediated immune response. Clin. Dev. Immunol. 2013,
186872. doi: 10.1155/2013/186872
Guo, H., Ingolia, N. T., Weissman, J. S., and Bartel, D. P. (2010). Mammalian
microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835–
840. doi: 10.1038/nature09267
Hafez, M. M., Hassan, Z. K., Zekri, A. R., Gaber, A. A., Al Rejaie, S. S., Sayed-
Ahmed, M. M., et al. (2012). MicroRNAs and metastasis-related gene expression
in Egyptian breast cancer patients. Asian Pac. J. Cancer Prev. 13, 591–598. doi:
10.7314/APJCP.2012.13.2.591
Han, M., Liu, M., Wang,Y., Chen, X., Xu, J., Sun,Y., et al. (2012). Antagonism of miR-
21 reverses epithelial–mesenchymal transition and cancer stem cell phenotype
through AKT/ERK1/2 inactivation by targeting PTEN. PLoS ONE 7:e39520. doi:
10.1371/journal.pone.0039520
Harris, T. A., Yamakuchi, M., Ferlito, M., Mendell, J. T., and Lowenstein,
C. J. (2008). MicroRNA-126 regulates endothelial expression of vascular cell
adhesion molecule 1. Proc. Natl. Acad. Sci. U.S.A. 105, 1516–1521. doi:
10.1073/pnas.0707493105
Hausmann, O. N. (2003). Post-traumatic inflammation following spinal cord injury.
Spinal Cord 41, 369–378. doi: 10.1038/sj.sc.3101483
Hong, J., Zhang, H., Kawase-Koga, Y., and Sun, T. (2013). MicroRNA function is
required for neurite outgrowth of mature neurons in the mouse postnatal cerebral
cortex. Front. Cell. Neurosci. 7:151. doi: 10.3389/fncel.2013.00151
Hu, J. R., Lv, G. H., and Yin, B. L. (2013a). Altered microRNA expression in the
ischemic-reperfusion spinal cord with atorvastatin therapy. J. Pharmacol. Sci.
121, 343–346. doi: 10.1254/jphs.12235SC
Hu, J. Z., Huang, J. H., Zeng, L., Wang, G., Cao, M., and Lu, H. B. (2013b). Anti-
apoptotic effect of microRNA-21 after contusion spinal cord injury in rats. J.
Neurotrauma 30, 1349–1360. doi: 10.1089/neu.2012.2748
Hutchison, E. R., Kawamoto, E. M., Taub, D. D., Lal, A., Abdelmohsen, K., Zhang, Y.,
et al. (2013). Evidence for miR-181 involvement in neuroinflammatory responses
of astrocytes. Glia 61, 1018–1028. doi: 10.1002/glia.22483
Hydbring, P., and Badalian-Very, G. (2013). Clinical applications of microRNAs.
F1000Research 2, 136. doi: 10.12688/f1000research.2-136.v3
Iliopoulos, D., Hirsch, H. A., and Struhl, K. (2009). An epigenetic switch
involving NF-kappaB, lin28, Let-7 microRNA, and IL6 links inflamma-
tion to cell transformation. Cell 139, 693–706. doi: 10.1016/j.cell.2009.
10.014
Iliopoulos, D., Jaeger, S. A., Hirsch, H. A., Bulyk, M. L., and Struhl, K. (2010).
STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of
the epigenetic switch linking inflammation to cancer. Mol. Cell 39, 493–506. doi:
10.1016/j.molcel.2010.07.023
Im, Y. B., Jee, M. K., Choi, J. I., Cho, H. T., Kwon, O. H., and Kang, S. K. (2012).
Molecular targeting of NOX4 for neuropathic pain after traumatic injury of the
spinal cord. Cell Death Dis. 3, e426. doi: 10.1038/cddis.2012.168
Iyer, A., Zurolo, E., Prabowo, A., Fluiter, K., Spliet, W. G., van Rijen, P. C., et al.
(2012). MicroRNA-146a: a key regulator of astrocyte-mediated inflammatory
response. PLoS ONE 7:e44789. doi: 10.1371/journal.pone.0044789
Izumi, B., Nakasa, T., Tanaka, N., Nakanishi, K., Kamei, N., Yamamoto, R.,
et al. (2011). MicroRNA-223 expression in neutrophils in the early phase of
secondary damage after spinal cord injury. Neurosci. Lett. 492, 114–118. doi:
10.1016/j.neulet.2011.01.068
Jee, M. K., Jung, J. S., Choi, J. I., Jang, J. A., Kang, K. S., Im, Y. B., et al. (2012a).
MicroRNA 486 is a potentially novel target for the treatment of spinal cord injury.
Brain , 135, 1237–1252. doi: 10.1093/brain/aws047
Jee, M. K., Jung, J. S., Im, Y. B., Jung, S. J., and Kang, S. K. (2012b). Silencing
of miR20a is crucial for Ngn1-mediated neuroprotection in injured spinal cord.
Hum. Gene Ther. 23, 508–520. doi: 10.1089/hum.2011.121
Jeyaseelan, K., Lim, K. Y., and Armugam, A. (2008). MicroRNA expression in
the blood and brain of rats subjected to transient focal ischemia by middle
cerebral artery occlusion. Stroke 39, 959–966. doi: 10.1161/STROKEAHA.107.
500736
Jia, Z., Zhu, H., Li, J., Wang, X., Misra, H., and Li, Y. (2012). Oxidative stress in
spinal cord injury and antioxidant-based intervention. Spinal Cord 50, 264–274.
doi: 10.1038/sc.2011.111
Jones, T. B., McDaniel, E. E., and Popovich, P. G. (2005). Inflammatory-mediated
injury and repair in the traumatically injured spinal cord. Curr. Pharm. Des. 11,
1223–1236. doi: 10.2174/1381612053507468
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 53 | 16
Nieto-Diaz et al. MicroRNAs in spinal cord injury
Junker, A., Krumbholz, M., Eisele, S., Mohan, H., Augstein, F., Bittner, R., et al.
(2009). MicroRNA profiling of multiple sclerosis lesions identifies modulators of
the regulatory protein CD47. Brain 132, 3342–3352. doi: 10.1093/brain/awp300
Kaur, P., Armugam, A., and Jeyaseelan, K. (2012). MicroRNAs in neurotoxicity. J.
Toxicol. 2012, 870150. doi: 10.1155/2012/870150
Kim,Y. K.,Yu, J., Han, T. S., Park, S. Y., Namkoong, B., Kim, D. H., et al. (2009). Func-
tional links between clustered microRNAs: suppression of cell-cycle inhibitors
by microRNA clusters in gastric cancer. Nucleic Acids Res. 37, 1672–1681. doi:
10.1093/nar/gkp002
Kirschner, M. B., Kao, S. C., Edelman, J. J., Armstrong, N. J., Vallely, M. P., van Zand-
wijk, N., et al. (2011). Haemolysis during sample preparation alters microRNA
content of plasma. PLoS ONE 6:e24145. doi: 10.1371/journal.pone.0024145
Kosaka, N., Iguchi, H., and Ochiya, T. (2010). Circulating microRNA in body fluid:
a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101,
2087–2092. doi: 10.1111/j.1349-7006.2010.01650.x
Kosik, K. S. (2006). The neuronal microRNA system. Nat. Rev. Neurosci. 7, 911–920.
doi: 10.1038/nrn2037
Kosik, K. S. (2010). MicroRNAs and cellular phenotypy. Cell 143, 21–26. doi:
10.1016/j.cell.2010.09.008
Kozomara, A., and Griffiths-Jones, S. (2011). miRBase: integrating microRNA
annotation and deep-sequencing data. Nucleic Acids Res. 39, D152–D157. doi:
10.1093/nar/gkq1027
Krek, A., Grun, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., et al.
(2005). Combinatorial microRNA target predictions. Nat. Genet. 37, 495–500.
doi: 10.1038/ng1536
Krichevsky, A. M. (2007). MicroRNA profiling: from dark matter to white matter, or
identifying new players in neurobiology. ScientificWorldJournal 7, 155–166. doi:
10.1100/tsw.2007.201
Krichevsky, A. M., King, K. S., Donahue, C. P., Khrapko, K., and Kosik, K. S.
(2003). A microRNA array reveals extensive regulation of microRNAs during
brain development. RNA 9, 1274–1281. doi: 10.1261/rna.5980303
Krichevsky, A. M., Sonntag, K. C., Isacson, O., and Kosik, K. S. (2006). Specific
microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells 24,
857–864. doi: 10.1634/stemcells.2005-0441
Krol, J., Loedige, I., and Filipowicz, W. (2010). The widespread regulation of
microRNA biogenesis, function and decay. Nat. Rev. Genet. 11, 597–610. doi:
10.1038/nrg2843
Kusuda, R., Cadetti, F., Ravanelli, M. I., Sousa, T. A., Zanon, S., De Lucca, F. L., et al.
(2011). Differential expression of microRNAs in mouse pain models. Mol. Pain
7, 17. doi: 10.1186/1744-8069-7-17
Laterza, O. F., Lim, L., Garrett-Engele, P. W., Vlasakova, K., Muniappa, N., Tanaka,
W. K., et al. (2009). Plasma MicroRNAs as sensitive and specific biomarkers of
tissue injury. Clin. Chem. 55, 1977–1983. doi: 10.1373/clinchem.2009.131797
Lau, P., Verrier, J. D., Nielsen, J. A., Johnson, K. R., Notterpek, L., and Hud-
son, L. D. (2008). Identification of dynamically regulated microRNA and mRNA
networks in developing oligodendrocytes. J. Neurosci. 28, 11720–11730. doi:
10.1523/JNEUROSCI.1932-08.2008
Lee, B. B., Cripps, R. A., Fitzharris, M., and Wing, P. C. (2013). The global map for
traumatic spinal cord injury epidemiology: update 2011, global incidence rate.
Spinal Cord 110–116. doi: 10.1038/sc.2012.158
Lee, E. J., Baek, M., Gusev, Y., Brackett, D. J., Nuovo, G. J., and Schmittgen, T. D.
(2008). Systematic evaluation of microRNA processing patterns in tissues, cell
lines, and tumors. RNA 14, 35–42. doi: 10.1261/rna.804508
Lee, R. C., Feinbaum, R. L., and Ambros, V. (1993). The C. elegans heterochronic
gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75,
843–854. doi: 10.1016/0092-8674(93)90529-Y
Li, H., Huang, S., Guo, C., Guan, H., and Xiong, C. (2012). Cell-free semi-
nal mRNA and microRNA exist in different forms. PLoS ONE 7:e34566. doi:
10.1371/journal.pone.0034566
Li, H., Shen, L., Ma, C., and Huang, Y. (2013). Differential expression of miRNAs in
the nervous system of a rat model of bilateral sciatic nerve chronic constriction
injury. Int. J. Mol. Med. 32, 219–226. doi: 10.3892/ijmm.2013.1381
Li, X., and Jin, P. (2010). Roles of small regulatory RNAs in determining neuronal
identity. Nat. Rev. Neurosci. 11, 329–338. doi: 10.1038/nrn2739
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle,
J., et al. (2005). Microarray analysis shows that some microRNAs downregu-
late large numbers of target mRNAs. Nature 433, 769–773. doi: 10.1038/nature
03315
Lindsay, M. A. (2008). microRNAs and the immune response. Trends Immunol. 29,
343–351. doi: 10.1016/j.it.2008.04.004
Liu, N. K., Wang, X. F., Lu, Q. B., and Xu, X. M. (2009). Altered microRNA
expression following traumatic spinal cord injury. Exp. Neurol. 219, 424–429.
doi: 10.1016/j.expneurol.2009.06.015
Liu, X. Z., Xu, X. M., Hu, R., Du, C., Zhang, S. X., McDonald, J. W., et al. (1997).
Neuronal and glial apoptosis after traumatic spinal cord injury. J. Neurosci. 17,
5395–5406.
Liu, Y., Chen, Q., Song, Y., Lai, L., Wang, J., Yu, H., et al. (2011). MicroRNA-98 neg-
atively regulates IL-10 production and endotoxin tolerance in macrophages after
LPS stimulation. FEBS Lett. 585, 1963–1968. doi: 10.1016/j.febslet.2011.05.029
Liverman, C. T., Altevogt, B. M., Joy, J. E., and Johnson, R. T. (2005). Spinal Cord
Injury: Progress, Promise, and Priorities. Washington, DC: National Academies
Press.
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. (2005).
MicroRNA expression profiles classify human cancers. Nature 435, 834–838. doi:
10.1038/nature03702
Lu, P., Nakorchevskiy, A., and Marcotte, E. M. (2003). Expression deconvo-
lution: a reinterpretation of DNA microarray data reveals dynamic changes
in cell populations. Proc. Natl. Acad. Sci. U.S.A. 100, 10370–10375. doi:
10.1073/pnas.1832361100
Ma, X., Becker Buscaglia, L. E., Barker, J. R., and Li, Y. (2010). MicroRNAs in NF-κB
signaling. J. Mol. Cell Biol. 3, 159–166. doi: 10.1093/jmcb/mjr007
Makeyev, E. V., Zhang, J., Carrasco, M. A., and Maniatis, T. (2007). The MicroRNA
miR-124 promotes neuronal differentiation by triggering brain-specific alter-
native pre-mRNA splicing. Mol. Cell 27, 435–448. doi: 10.1016/j.molcel.2007.
07.015
Mann, R., Schaefer, C., Sadosky, A., Bergstrom, F., Baik, R., Parsons, B., et al.
(2013). Burden of spinal cord injury-related neuropathic pain in the United States:
retrospective chart review and cross-sectional survey. Spinal Cord 51, 564–570.
doi: 10.1038/sc.2013.34
Mautes, A. E., Weinzierl, M. R., Donovan, F., and Noble, L. J. (2000). Vascular events
after spinal cord injury: contribution to secondary pathogenesis. Phys. Ther. 80,
673–687.
McTigue, D. M., Popovich, P. G., Morgan, T. E., and Stokes, B. T. (2000).
Localization of transforming growth factor-beta1 and receptor mRNA after
experimental spinal cord injury. Exp. Neurol. 163, 220–230. doi: 10.1006/exnr.
2000.7372
Merkerova, M., Belickova, M., and Bruchova, H. (2008). Differential expression of
microRNAs in hematopoietic cell lineages. Eur. J. Haematol. 81, 304–310. doi:
10.1111/j.1600-0609.2008.01111.x
Mestdagh, P., Bostrom, A. K., Impens, F., Fredlund, E., Van Peer, G., De Antonellis,
P., et al. (2010). The miR-17-92 microRNA cluster regulates multiple compo-
nents of the TGF-β pathway in neuroblastoma. Mol. Cell 40, 762–773. doi:
10.1016/j.molcel.2010.11.038
Meza-Sosa, K. F., Valle-Garcia, D., Pedraza-Alva, G., and Perez-Martinez, L. (2012).
Role of microRNAs in central nervous system development and pathology.
J. Neurosci. Res. 90, 1–12. doi: 10.1002/jnr.22701
Miska, E. A., Alvarez-Saavedra, E., Townsend, M., Yoshii, A., Sestan, N., Rakic,
P., et al. (2004). Microarray analysis of microRNA expression in the developing
mammalian brain. Genome Biol. 5, R68. doi: 10.1186/gb-2004-5-9-r68
Morel, L., Regan, M., Higashimori, H., Ng, S. K., Esau, C., Vidensky, S.,
et al. (2013). Neuronal exosomal miRNA-dependent translational regulation
of astroglial glutamate transporter GLT1. J. Biol. Chem. 288, 7105–7116. doi:
10.1074/jbc.M112.410944
Nakanishi, K., Nakasa, T., Tanaka, N., Ishikawa, M., Yamada, K., Yamasaki, K., et al.
(2010). Responses of microRNAs 124a and 223 following spinal cord injury in
mice. Spinal Cord 48, 192–196. doi: 10.1038/sc.2009.89
Oyinbo, C. A. (2011). Secondary injury mechanisms in traumatic spinal cord injury:
a nugget of this multiply cascade. Acta Neurobiol. Exp. (Wars) 71, 281–299.
Pekny, M., and Pekna, M. (2004). Astrocyte intermediate filaments in CNS
pathologies and regeneration. J. Pathol. 204, 428–437. doi: 10.1002/path.1645
Perri, R., Nares, S., Zhang, S., Barros, S. P., and Offenbacher, S. (2012).
MicroRNA modulation in obesity and periodontitis. J. Dent. Res. 91, 33–38.
doi: 10.1177/0022034511425045
Pogue, A. I., Cui, J. G., Li, Y. Y., Zhao, Y., Culicchia, F., and Lukiw, W. J. (2010). Micro
RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation.
Neurosci. Lett. 476, 18–22. doi: 10.1016/j.neulet.2010.03.054
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 53 | 17
Nieto-Diaz et al. MicroRNAs in spinal cord injury
Ponomarev, E. D., Veremeyko, T., Barteneva, N., Krichevsky, A. M., and Weiner,
H. L. (2011). MicroRNA-124 promotes microglia quiescence and suppresses EAE
by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat. Med. 17,
64–70. doi: 10.1038/nm.2266
Pritchard, C. C., Cheng, H. H., and Tewari, M. (2012). MicroRNA profil-
ing: approaches and considerations. Nat. Rev. Genet. 13, 358–369. doi:
10.1038/nrg3198
Profyris, C., Cheema, S. S., Zang, D., Azari, M. F., Boyle, K., and Petratos, S.
(2004). Degenerative and regenerative mechanisms governing spinal cord injury.
Neurobiol. Dis. 15, 415–436. doi: 10.1016/j.nbd.2003.11.015
Qiu, J., Nesic, O., Ye, Z., Rea, H., Westlund, K. N., Xu, G. Y., et al. (2001). Bcl-xL
expression after contusion to the rat spinal cord. J. Neurotrauma 18, 1267–1278.
doi: 10.1089/089771501317095304
Redell, J. B., Moore, A. N., Ward, N. H. III, Hergenroeder, G. W., and Dash,
P. K. (2010). Human traumatic brain injury alters plasma microRNA levels.
J. Neurotrauma 27, 2147–2156. doi: 10.1089/neu.2010.1481
Rowland, J. W., Hawryluk, G. W., Kwon, B., and Fehlings, M. G. (2008). Current sta-
tus of acute spinal cord injury pathophysiology and emerging therapies: promise
on the horizon. Neurosurg. Focus 25, E2. doi: 10.3171/FOC.2008.25.11.E2
Sahni, V., Mukhopadhyay, A., Tysseling, V., Hebert, A., Birch, D., McGuire, T. L., et al.
(2010). BMPR1a and BMPR1b signaling exert opposing effects on gliosis after
spinal cord injury. J. Neurosci. 30, 1839–1855. doi: 10.1523/JNEUROSCI.4459-
09.2010
Saito, N., Yamamoto, T., Watanabe, T., Abe, Y., and Kumagai, T. (2000). Implications
of p53 protein expression in experimental spinal cord injury. J. Neurotrauma 17,
173–182. doi: 10.1089/neu.2000.17.173
Saito, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., Coetzee, G. A., et al.
(2006). Specific activation of microRNA-127 with downregulation of the proto-
oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer
Cell 9, 435–443. doi: 10.1016/j.ccr.2006.04.020
Santoscoy, C., Rios, C., Franco-Bourland, R. E., Hong, E., Bravo, G., Rojas, G., et al.
(2002). Lipid peroxidation by nitric oxide supplements after spinal cord injury:
effect of antioxidants in rats. Neurosci. Lett. 330, 94–98. doi: 10.1016/S0304-
3940(02)00716-4
Saugstad, J. A. (2010). MicroRNAs as effectors of brain function with roles in
ischemia and injury, neuroprotection, and neurodegeneration. J. Cereb. Blood
Flow Metab. 30, 1564–1576. doi: 10.1038/jcbfm.2010.101
Saugstad, J. A. (2013). MicroRNAs as effectors of brain function. Stroke 44(Suppl.
1), S17–S19. doi: 10.1161/STROKEAHA.113.000985
Sayed, D., and Abdellatif, M. (2011). MicroRNAs in development and disease.
Physiol. Rev. 91, 827–887. doi: 10.1152/physrev.00006.2010
Scholz, J., and Woolf, C. J. (2007). The neuropathic pain triad: neurons, immune
cells and glia. Nat. Neurosci. 10, 1361–1368. doi: 10.1038/nn1992
Selbach, M., Schwanhausser, B., Thierfelder, N., Fang, Z., Khanin, R., and Rajew-
sky, N. (2008). Widespread changes in protein synthesis induced by microRNAs.
Nature 455, 58–63. doi: 10.1038/nature07228
Sempere, L. F., Freemantle, S., Pitha-Rowe, I., Moss, E., Dmitrovsky, E., and
Ambros, V. (2004). Expression profiling of mammalian microRNAs uncov-
ers a subset of brain-expressed microRNAs with possible roles in murine and
human neuronal differentiation. Genome Biol. 5, R13. doi: 10.1186/gb-2004-
5-3-r13
Sharma, A., Kumar, M., Aich, J., Hariharan, M., Brahmachari, S. K., Agrawal, A., et al.
(2009). Posttranscriptional regulation of interleukin-10 expression by hsa-miR-
106a. Proc. Natl. Acad. Sci. U.S.A. 106, 5761–5766. doi: 10.1073/pnas.0808743106
Sheedy, F. J., Palsson-McDermott, E., Hennessy, E. J., Martin, C., O’Leary, J. J., Ruan,
Q., et al. (2010). Negative regulation of TLR4 via targeting of the proinflammatory
tumor suppressor PDCD4 by the microRNA miR-21. Nat. Immunol. 11, 141–147.
doi: 10.1038/ni.1828
Shin, D., Shin, J. Y., McManus, M. T., Ptacek, L. J., and Fu,Y. H. (2009). Dicer ablation
in oligodendrocytes provokes neuronal impairment in mice. Ann. Neurol. 66,
843–857. doi: 10.1002/ana.21927
Shu, J., Kren, B. T., Xia, Z., Wong, P. Y., Li, L., Hanse, E. A., et al. (2011). Genomewide
microRNA down-regulation as a negative feedback mechanism in the early phases
of liver regeneration. Hepatology 54, 609–619. doi: 10.1002/hep.24421
Silver, J., and Miller, J. H. (2004). Regeneration beyond the glial scar. Nat. Rev.
Neurosci. 5, 146–156. doi: 10.1038/nrn1326
Sluijter, J. P. G. (2013). MicroRNAs in cardiovascular regenerative medicine:
directing tissue repair and cellular differentiation. ISRN Vasc. Med. 2013, 16.
Smirnova, L., Grafe, A., Seiler, A., Schumacher, S., Nitsch, R., and Wulczyn, F. G.
(2005). Regulation of miRNA expression during neural cell specification. Eur. J.
Neurosci. 21, 1469–1477. doi: 10.1111/j.1460-9568.2005.03978.x
Smith, B., Treadwell, J., Zhang, D., Ly, D., McKinnell, I., Walker, P. R.,
et al. (2010). Large-scale expression analysis reveals distinct microRNA pro-
files at different stages of human neurodevelopment. PLoS ONE 5:e11109. doi:
10.1371/journal.pone.0011109
Sofroniew, M. V. (2005). Reactive astrocytes in neural repair and protection.
Neuroscientist 11, 400–407. doi: 10.1177/1073858405278321
Sofroniew, M. V. (2009). Molecular dissection of reactive astrogliosis and glial scar
formation. Trends Neurosci. 32, 638–647. doi: 10.1016/j.tins.2009.08.002
Song, G., Cechvala, C., Resnick, D. K., Dempsey, R. J., and Rao, V. L. (2001).
GeneChip analysis after acute spinal cord injury in rat. J. Neurochem. 79, 804–815.
doi: 10.1046/j.1471-4159.2001.00626.x
Sonkoly, E., and Pivarcsi, A. (2009). microRNAs in inflammation. Int. Rev. Immunol.
28, 535–561. doi: 10.3109/08830180903208303
Stefani, G., and Slack, F. J. (2008). Small non-coding RNAs in animal development.
Nat. Rev. Mol. Cell Biol. 9, 219–230. doi: 10.1038/nrm2347
Strickland, E. R., Hook, M. A., Balaraman, S., Huie, J. R., Grau, J. W., and
Miranda, R. C. (2011). MicroRNA dysregulation following spinal cord contu-
sion: implications for neural plasticity and repair. Neuroscience 186, 146–160.
doi: 10.1016/j.neuroscience.2011.03.063
Sugawara, T., Lewen, A., Gasche, Y., Yu, F., and Chan, P. H. (2002). Overexpression of
SOD1 protects vulnerable motor neurons after spinal cord injury by attenuating
mitochondrial cytochrome c release. FASEB J. 16, 1997–1999.
Taganov, K. D., Boldin, M. P., Chang, K. J., and Baltimore, D. (2006). NF-κB-
dependent induction of microRNA miR-146, an inhibitor targeted to signaling
proteins of innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 103, 12481–
12486. doi: 10.1073/pnas.0605298103
Tao, J., Wu, H., Lin, Q., Wei, W., Lu, X. H., Cantle, J. P., et al. (2011). Deletion of
astroglial dicer causes non-cell-autonomous neuronal dysfunction and degener-
ation. J. Neurosci. 31, 8306–8319. doi: 10.1523/JNEUROSCI.0567-11.2011
Taoka, Y., Okajima, K., Uchiba, M., Murakami, K., Kushimoto, S., Johno, M., et al.
(1997). Role of neutrophils in spinal cord injury in the rat. Neuroscience 79,
1177–1182. doi: 10.1016/S0306-4522(97)00011-0
Tili, E., Michaille, J. J., Cimino, A., Costinean, S., Dumitru, C. D., Adair,
B., et al. (2007). Modulation of miR-155 and miR-125b levels following
lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating
the response to endotoxin shock. J. Immunol. 179, 5082–5089.
Treiber, T., Treiber, N., and Meister, G. (2012). Regulation of microRNA biogenesis
and function. Thromb. Haemost. 107, 605–610. doi: 10.1160/TH11-12-0836
Tsang, J. S., Ebert, M. S., and van Oudenaarden, A. (2010). Genome-wide dissection
of microRNA functions and cotargeting networks using gene set signatures. Mol.
Cell 38, 140–153. doi: 10.1016/j.molcel.2010.03.007
Tyor, W. R., Avgeropoulos, N., Ohlandt, G., and Hogan, E. L. (2002). Treatment
of spinal cord impact injury in the rat with transforming growth factor-beta.
J. Neurol. Sci. 200, 33–41. doi: 10.1016/S0022-510X(02)00113-2
Velardo, M. J., Burger, C., Williams, P. R., Baker, H. V., Lopez, M. C., Mareci, T.
H., et al. (2004). Patterns of gene expression reveal a temporally orchestrated
wound healing response in the injured spinal cord. J. Neurosci. 24, 8562–8576.
doi: 10.1523/JNEUROSCI.3316-04.2004
Visvanathan, J., Lee, S., Lee, B., Lee, J. W., and Lee, S. K. (2007). The microRNA miR-
124 antagonizes the anti-neural REST/SCP1 pathway during embryonic CNS
development. Genes Dev. 21, 744–749. doi: 10.1101/gad.1519107
Wang, J., Gu, Z., Ni, P., Qiao, Y., Chen, C., Liu, X., et al. (2011). NF-κB P50/P65
hetero-dimer mediates differential regulation of CD166/ALCAM expression via
interaction with micoRNA-9 after serum deprivation, providing evidence for
a novel negative auto-regulatory loop. Nucleic Acids Res. 39, 6440–6455. doi:
10.1093/nar/gkr302
Wang, M., Master, S. R., and Chodosh, L. A. (2006). Computational expression
deconvolution in a complex mammalian organ. BMC Bioinformatics 7:328. doi:
10.1186/1471-2105-7-328
Wang, Z. (2010). MicroRNA: a matter of life or death. World J. Biol. Chem. 1, 41–54.
doi: 10.4331/wjbc.v1.i4.41
Willemen, H. L., Huo, X. J., Mao-Ying, Q. L., Zijlstra, J., Heijnen, C.
J., and Kavelaars, A. (2012). MicroRNA-124 as a novel treatment for per-
sistent hyperalgesia. J. Neuroinflammation 9, 143. doi: 10.1186/1742-2094-
9-143
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 53 | 18
Nieto-Diaz et al. MicroRNAs in spinal cord injury
Wu, C. I., Shen, Y., and Tang, T. (2009). Evolution under canalization and
the dual roles of microRNAs: a hypothesis. Genome Res. 19, 734–743. doi:
10.1101/gr.084640.108
Wu, H., Neilson, J. R., Kumar, P., Manocha, M., Shankar, P., Sharp, P. A., et al. (2007).
miRNA profiling of naive, effector and memory CD8 T cells. PLoS ONE 2:e1020.
doi: 10.1371/journal.pone.0001020
Wu, X., Yoo, S., and Wrathall, J. R. (2005). Real-time quantitative PCR analysis
of temporal-spatial alterations in gene expression after spinal cord contusion.
J. Neurochem. 93, 943–952. doi: 10.1111/j.1471-4159.2005.03078.x
Xiao, Q., Du, Y., Wu, W., and Yip, H. K. (2010). Bone morphogenetic
proteins mediate cellular response and, together with Noggin, regulate astro-
cyte differentiation after spinal cord injury. Exp. Neurol. 221, 353–366. doi:
10.1016/j.expneurol.2009.12.003
Yang, L., Jones, N. R., Blumbergs, P. C., Van Den Heuvel, C., Moore, E. J., Manavis,
J., et al. (2005). Severity-dependent expression of pro-inflammatory cytokines
in traumatic spinal cord injury in the rat. J. Clin. Neurosci. 12, 276–284. doi:
10.1016/j.jocn.2004.06.011
Young, M. R., Santhanam, A. N., Yoshikawa, N., and Colburn, N. H. (2010). Have
tumor suppressor PDCD4 and its counteragent oncogenic miR-21 gone rogue?
Mol. Interv. 10, 76–79. doi: 10.1124/mi.10.2.5
Yu, J. Y., Chung, K. H., Deo, M., Thompson, R. C., and Turner, D. L. (2008).
MicroRNA miR-124 regulates neurite outgrowth during neuronal differentiation.
Exp. Cell Res. 314, 2618–2633. doi: 10.1016/j.yexcr.2008.06.002
Yu, Y. M., Gibbs, K. M., Davila, J., Campbell, N., Sung, S., Todorova, T. I., et al.
(2011). MicroRNA miR-133b is essential for functional recovery after spinal cord
injury in adult zebrafish. Eur. J. Neurosci. 33, 1587–1597. doi: 10.1111/j.1460-
9568.2011.07643.x
Yunta, M., Nieto-Diaz, M., Esteban, F. J., Caballero-Lopez, M., Navarro-Ruiz, R.,
Reigada, D., et al. (2012). MicroRNA dysregulation in the spinal cord following
traumatic injury. PLoS ONE 7:e34534. doi: 10.1371/journal.pone.0034534
Zamanian, J. L., Xu, L., Foo, L. C., Nouri, N., Zhou, L., Giffard, R. G., et al.
(2012). Genomic analysis of reactive astrogliosis. J. Neurosci. 32, 6391–6410. doi:
10.1523/JNEUROSCI.6221-11.2012
Zampetaki, A., and Mayr, M. (2012). Analytical challenges and technical limita-
tions in assessing circulating miRNAs. Thromb. Haemost. 108, 592–598. doi:
10.1160/TH12-02-0097
Zhang, K. H., Xiao, H. S., Lu, P. H., Shi, J., Li, G. D., Wang, Y. T., et al. (2004).
Differential gene expression after complete spinal cord transection in adult rats:
an analysis focused on a subchronic post-injury stage. Neuroscience 128, 375–388.
doi: 10.1016/j.neuroscience.2004.07.008
Zhang, Y., Liao, Y., Wang, D., He, Y., Cao, D., Zhang, F., et al. (2011). Altered
expression levels of miRNAs in serum as sensitive biomarkers for early diagnosis
of traumatic injury. J. Cell. Biochem. 112, 2435–2442. doi: 10.1002/jcb.23168
Zhao, C., Sun, G., Li, S., Lang, M. F., Yang, S., Li, W., et al. (2010a). MicroRNA
let-7b regulates neural stem cell proliferation and differentiation by targeting
nuclear receptor TLX signaling. Proc. Natl. Acad. Sci. U.S.A. 107, 1876–1881. doi:
10.1073/pnas.0908750107
Zhao, X., He, X., Han, X., Yu, Y., Ye, F., Chen, Y., et al. (2010b). MicroRNA-
mediated control of oligodendrocyte differentiation. Neuron 65, 612–626. doi:
10.1016/j.neuron.2010.02.018
Zhu, H., and Fan, G. C. (2011). Extracellular/circulating microRNAs and their
potential role in cardiovascular disease. Am. J. Cardiovasc. Dis. 1, 138–149.
Ziu, M., Fletcher, L., Savage, J. G., Jimenez, D. F., Digicaylioglu, M., and
Bartanusz, V. (2013). Spatial and temporal expression levels of specific microR-
NAs in a spinal cord injury mouse model and their relationship to the
duration of compression. Spine J. 14, 353–360. doi: 10.1016/j.spinee.2013.
08.015
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 15 December 2013; accepted: 06 February 2014; published online: 25
February 2014.
Citation: Nieto-Diaz M, Esteban FJ, Reigada D, Muñoz-Galdeano T, Yunta M,
Caballero-López M, Navarro-Ruiz R, del Águila Á and Maza RM (2014) MicroRNA
dysregulation in spinal cord injury: causes, consequences, and therapeutics. Front. Cell.
Neurosci. 8:53. doi: 10.3389/fncel.2014.00053
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2014 Nieto-Diaz, Esteban, Reigada, Muñoz-Galdeano, Yunta, Caballero-
López, Navarro-Ruiz, del Águila and Maza. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 53 | 19
